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ABSTRACT 
 
Deitz, Samantha L. M.S., Purdue University, August 2012. Molecular Basis and 
Modification of a Neural Crest Deficit in a Down Syndrome Mouse Model. Major 
Professor: Randall J. Roper. 
 
 
 
Down syndrome (DS) is the result of trisomy of human chromosome 21 (Hsa 21) 
and occurs in approximately 1/700 live births. Mouse models of DS have been crucial in 
understanding the gene-phenotype relationships that underlie many DS anomalies. The 
Ts65Dn mouse model, trisomic for half of the Hsa 21 orthologs, replicates many DS 
phenotypes including craniofacial alterations such as a small, dysmorphic mandible, 
midface, and maxilla. Other mouse models, such as the Ts1Rhr which contains a 
triplication of 33 Hsa 21 orthologs, have been used to better understand the genes 
responsible for craniofacial alterations. Our laboratory has demonstrated that the 
postnatal mandibular phenotype found in Ts65Dn mice can be traced back to an original 
neural crest cell (NCC) deficit in the developing first pharyngeal arch (PA1) at embryonic 
day 9.5 (E9.5). Furthermore, evidence suggested that both a proliferation deficit in the 
PA1 and a migration deficit of NCC from the neural tube (NT) could be the mechanism 
behind this deficit. However, the molecular mechanisms behind these deficits remain to 
be elucidated. Due to the involvement of the Hsa 21 genes DYRK1A and RCAN1 in 
x 
 
x 
regulation of signaling pathways including NFATc (NFAT2), a transcription factor known 
to influence cellular proliferation and, later, bone development, we hypothesized that 
dysregulation of these genes could underlie to cellular deficit in the PA1. Furthermore, 
we hypothesized targeting Dyrk1a by decreasing activity or available protein could 
ameliorate the established deficits. 
 Through the use of RNA isolation techniques and cell culture systems of cells 
from the PA1 and NT of E9.5 Ts65Dn, Ts1Rhr, and control embryos, we established that 
trisomic genes Dyrk1a and Rcan1 are dysregulated in both structures and that these two 
genes may interact. Furthermore, we established that a proliferation deficit in the 
Ts65Dn PA1 and a migration deficit in the Ts65Dn PA1 and NT exists at E9.5 and can be 
rescued to euploid levels in vitro with the addition of the Dyrk1a inhibitor, EGCG, a 
green tea polyphenol. We also confirmed that harmine, a more highly studied and 
specific Dyrk1a inhibitor, is capable of similar effects on proliferation of PA1 cells from 
E9.5 Ts65Dn embryos. Furthermore, when Ts65Dn pregnant mothers were treated with 
EGCG in vivo, the cellular deficit found in the developing E9.5 embryonic PA1 was 
rescued to near euploid volume and NCC number. Treatment with EGCG did not 
adversely impact litter size or embryonic development. Interestingly, euploid embryonic 
volume increased with EGCG treatment. Expression analysis of the E9.5 PA1 of EGCG 
treated Ts65Dn and control embryos revealed dysregulation of several genes involved in 
craniofacial and developmental pathways including Dyrk1a, Rcan1, Ets2 and members of 
the sonic hedgehog pathway. Our novel results provide a foundation for better 
xi 
 
xi 
understanding the molecular mechanisms of craniofacial development and may provide 
evidence-based therapeutic options to improve the quality of life for individuals with DS.  
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CHAPTER 1. INTRODUCTION 
 
1.1 Down Syndrome 
 Down syndrome (DS) occurs in 1/700 live births and is the result of trisomy of 
human chromosome (Hsa) 21 (PARKER et al. 2010). This disorder is the most common 
genetic form of intellectual disability (ID) and has been well studied and characterized 
independently by genotype and phenotype (KORBEL et al. 2009; LYLE et al. 2009). DS was 
first coarsely described in 1846 by Édouard Onésimus Séguin, the first President of the 
current American Association for Mental Deficiency, as a form of cretinism, including 
‘shortcomings of the integuments…truncated fingers and nose’ which are reminiscent of 
DS, but does not irrevocably describe the syndrome itself (BERG and KOROSSY 2001; NERI 
and OPITZ 2009). The disorder was described ethnically by physician John Langdon Down, 
after whom the disorder was named, in 1866. In his observations, he stated that those 
he studied with what is now known as Down syndrome were ‘merely varieties of the 
human race having a common origin’ but that these individuals were derived from ‘the 
Mongolian great family’ based on his idea that these individuals resembled those from 
Mongolia who were once thought to have impeded development (DOWN 1866; 
MEGARBANE et al. 2009). The genetic cause of this disorder was not identified until 1959 
by Jerome Lejeune. With the advent of karyotyping techniques and a general need for 
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more fundamental explanation of the disorder’s origin, Lejeune set out to understand 
what genetic insult was responsible for these phenotypes. In 1959 he published that DS 
resulted from an extra chromosome 21, leading to the clinical condition of Trisomy 21 
(LEJEUNE et al. 1959a; LEJEUNE et al. 1959b). These results were later confirmed by 
numerous groups, followed by the observation that Trisomy 21 could also results from 
the additional presence of only a portion of Hsa 21 with regard to the normal genetic 
complement (MEGARBANE et al. 2009). Since the discovery of the initial genetic insult of 
the disorder, much research has taken place to better understand the mechanisms by 
which the third copy of Hsa 21 causes the phenotypes observed in individuals with DS. 
Though the genotype-phenotype relationships are not well understood in DS, 
the mechanism of transmission has been well-studied. The transmission of trisomy 
generally occurs through meiotic nondisjunction (95% of all cases) in meiosis I and II, of 
which 88% originates maternally, 8% paternally, and 4% mitotically (ANTONARAKIS 1991; 
MULLER et al. 2000). Less commonly, DS has also been shown to occur as an unbalanced 
Robertsonian translocation (under 5%) in which the long arm of Hsa 21 translocates 
with the long arm of Hsa 14, leading to the possibility of inheritance of Trisomy 21. This 
may occur more frequently in telocentric chromosomes such as 21 compared to 
acrocentric chromosomes, due to relative instability of the physical nature of the 
chromosome (CLARKE et al. 1989). In addition, mosaicism, which occurs in less than 1% of 
individuals with DS, results in some somatic cells which display the genetic abnormality 
while others maintain a diploid state. The origins of the mosaicism may stem from 
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either a normal zygote or trisomic zygote having undergone errors in mitosis at any of 
multiple cleavages early in development (Figure 1.1) (RICHARDS 1969).  
Several risk factors play a role in the development of Trisomy 21 which have 
been well described and continue to be investigated. A significant risk factor for 
maternal nondisjunction is the characteristic advanced maternal age (ALLEN et al. 2009). 
However, it should be noted that a majority of individuals with DS are born to younger 
women (under the age of 35 at delivery), due to a higher percentage of children born to 
younger mothers (Table 1.1) (AGOPIAN et al. 2012; HUETHER et al. 1998). Though only 
hypotheses, the reasoning for this risk has been attributed to the accumulation of 
environmental assaults in the oocyte, which have remained arrested in development or 
degradation of cell cycling machinery needed to complete meiosis I or II (SHERMAN et al. 
2005). Changes in the maternal genome, such as mutations in the gene encoding 
methylenetetrahydrofolate reductase, may subject mothers to an increased risk of 
having a child with DS (JAMES et al. 1999). This may be true of several aneuploidies due 
to the association of abnormal folate and methyl metabolism with DNA 
hypomethylation and abnormalities in chromosome segregation (CHRISTMAN et al. 1993; 
POGRIBNY et al. 1997). Paternal nondisjunction, though much less common than maternal 
nondisjunction, also may lead to 6-10% of cases of Trisomy 21 through errors in 
spermatogenesis, with equal occurrences of meiosis I and II cases (as opposed to 
maternal nondisjunction, occurring at a 3:1 ratio) (PETERSEN et al. 1993; SAVAGE et al. 
1998). Other hypothesized risk factors that have been identified include a father who is 
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between 20 and 24 years, compared to 25 to 29 years old, and Hispanic, as well as 
women with less than a high school education (AGOPIAN et al. 2012).  
Regardless, this genetic anomaly is easily identified in the first trimester through 
diagnostic tools such as amniocentesis, which samples the amnion containing fetal 
tissue, for analysis between 15 and 20 weeks gestation; chorionic villus sampling, which 
utilizes tissue from the placenta (fetal derived) for analysis at approximately 10-12 
weeks gestation; and several newly-developed non-invasive methods including 
multiplexed maternal plasma DNA sequencing, for use in high risk pregnancies (CHIU et 
al. 2011). In essence, multiplexed maternal plasma DNA sequencing works off the 
following principle: during pregnancy, DNA from the fetus is present in maternal blood 
in a cell-free form. In order to test for the presence of Trisomy 21, one would aim to 
detect a higher level of Hsa 21 sequence comparatively to other chromosomes from the 
fetus, only after distinguishing the fetal genome from the reference genome of the 
mother (CHIU et al. 2010). This technique also has broad impacts due to its ability to 
detect other genetic anomalies. Recently, the MaterniT21 PLUS test, validated by 
Sequenom CMM, was developed to sensitively test circulating fetal cell-free DNA in 
maternal blood, detecting 210 of 212 cases of Trisomy 21 at 99.1% sensitivity with uses 
also being developed to detect Trisomy 13 and Trisomy 18 using similar methods (EHRICH 
et al. 2011; PALOMAKI et al. 2011). In addition, ultrasound screenings can provide a non-
invasive diagnostic tool for the assessment of anatomical markers, such as nuchal 
thickening, increased nuchal lucency, and shortened long bones (KUBAS 1999). 
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Individuals with DS present with myriad phenotypes which occur in differing 
penetrance and severity between individuals and in multiple organ systems at different 
stages of development. All individuals display ID and craniofacial abnormalities, while 
approximately 45-50% of individuals display cardiac defects, most commonly including 
septal defects (EPSTEIN 2001; VAN CLEVE et al. 2006; VAN CLEVE and COHEN 2006). 
Furthermore, while some individuals with ID are only moderately impaired and may be 
able to function independently, other individuals have severe cognitive impairment and 
very few reach a near normal levels of cognitive and intellectual development in 
adulthood (DE et al. 2000; ROUBERTOUX and CARLIER 2010). Individuals with DS also present 
with higher instances of leukemia and Hirschprung disease than the general population 
(HASLE 2001) and display early-onset of Alzheimer disease(AD)-like pathology with all 
individuals with DS developing AD-like pathology over age 40 (WISNIEWSKI et al. 1985).  
Interestingly, not all individuals present with a full copy of Hsa 21 or presence of 
all three copies of Hsa21 in every cell, even though they are described as having DS. 
Individuals who display partial Trisomy 21 or mosaicism, respectively, typically display a 
milder phenotype than those individuals with full Trisomy 21 (DE et al. 2000; KOTZOT and 
SCHINZEL 2000; WILLIAMS et al. 1990) and contribute valuable information essential for 
understanding the genotype-phenotype correlations which underlie the basis of Down 
syndrome pathophysiology. For example, a man with low Trisomy 21 mosaicism 
currently functions with some clinical signs of DS with normal ID; however, he was 
diagnosed at birth due to his clinical features of the face and appendages, as well as 
hypotonia and impaired motor skills. Interestingly, he performed well throughout 
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regular schooling and in sports, and despite not finishing college, lives a relatively 
normal lifestyle despite his mosaicism (DE et al. 2000). In addition, an individual with a 
de novo, unbalanced translocation leading to a triplication involving the segment 21q11 
to 21q22.1, displayed mild phenotypes but not those typical of individuals with DS. 
Findings provided from this study indicated that duplication of the area from the 
centromere to 21q22.1 may be important in the development of some DS phenotypes 
(WILLIAMS et al. 1990), aiding in the understanding of genotype-phenotype relationships.  
Despite the phenotypes which appear to have a largely negative influence on 
health, individuals with DS display some physiological advantages over the normosomic 
population. While individuals with DS display a higher incidence of several types of 
cancer, including acute myeloid, lymphoblastic, and megakaryoblastic leukemias (HITZLER 
2007), retinoblastoma, and germ cell tumors (HASLE 2001), as a whole, individuals with 
DS display a lower incidence of solid tumors (HASLE 2001; SATGE and VEKEMANS 2011). 
 
1.2 Human Genotype-Phenotype Relationships 
  The understanding of how specific genes work either alone, in concert with 
genes on Hsa 21, or even with other genes throughout the rest of the genome is vital to 
proposing therapeutics for individual phenotypes for those with DS. Two major studies 
were key in establishing an understanding of these relationships in the early 1990s. 
Delabar and colleagues phenotypically and molecularly analyzed 10 individuals with 
partial Trisomy 21, identifying six regions for 24 features of DS, including short stature, 
joint hyperlaxity, hypotonia, ID, and craniofacial anomalies (DELABAR et al. 1993). The 
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resultant regions of interest spanned a 0.4-3Mb area on 21q22.2 to proximal 21q22.3 
and an approximate 6Mb region on 21q22.2 and part of 21q22.3 (DELABAR et al. 1993). It 
was originally purported that this one or more of the genes in this region was 
responsible for the major phenotypes associated with DS, including cognitive 
impairment, craniofacial dysmorphology (DELABAR et al. 1993). In addition, Korenberg 
and colleagues performed a similar study in which cell lines from 16 individuals with 
partial Trisomy 21 were molecularly analyzed and combined with clinical evaluations of 
these individuals to create a ‘phenotypic map’ which included 25 features of DS mapped 
to 2-20 Mb regions in which genes likely responsible for these phenotypes were found 
(KORENBERG et al. 1994). However, investigators have hypothesized that a single DS 
chromosomal region is likely not responsible for the typical features associated with DS 
(KORBEL et al. 2009; KORENBERG et al. 1994; LYLE et al. 2009). These studies laid the 
groundwork for understanding the involvement of one or multiple genes in the 
development of a specific phenotype and were instrumental in defining a region of the 
fewest number of genes purported to be responsible for the major phenotypes of DS, 
named the Down Syndrome Critical Region (DSCR). This region has since been triplicated 
in a DS mouse model to better understand its involvement in DS phenotypes. 
Several studies have recently aimed to increase the understanding of these 
relationships by use of mapping partial Trisomy 21 cases from humans, creating mouse 
models of partial trisomies which are orthologous to Hsa 21 genes, and analyzing tissue 
from individuals with DS and/or tissues from DS mouse models. High-resolution analysis 
of human segmental trisomies, comprised of an analysis of 30 individuals with rare 
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segmental trisomies and well characterized phenotypes, was performed by Korbel and 
colleagues to understand the contribution of small genetic segments to DS phenotypes. 
Through the compilation of karyotypes, fluorescence in situ hybridization (FISH) analysis 
to determine breakpoints and orientation, high resolution mapping via quantitative 
Southern blotting, and sequencing, a highly detailed description of each individual’s 
genetic signature was compared using the phenotypic map. Investigators identified 
regions of 1.8-16.3 Mb likely implicated in eight DS phenotypes, including Hirschsprung 
disease, severe ID, DS-related Alzheimer disease (AD), and DS-specific congenital heart 
disease (KORBEL et al. 2009). A similar study by Lyle and colleagues introduced the idea of 
susceptibility regions of the genome for DS phenotypes using similar methodologies 
(LYLE et al. 2009). Investigators found a region between positions 37.94 and 38.64 on 
Hsa21 containing the genes KCNJ6, DSCR4, and KCNJ15 as a susceptibility for ID, 
between 37.4 and 38.4 and 46.5 to qter for hypotonia, and 31.5 Mb to qter for 
congenital heart disease (Figure 1.2) (LYLE et al. 2009). These studies provided a vast 
amount of information, specifically in understanding which gene(s)/genetic regions may 
be responsible for a specific DS phenotype (KORBEL et al. 2009). 
An interesting example of single gene-phenotype relationships includes the Hsa 
21 gene synaptojanin-1 (SYNJ1) which illustrates the importance of single genes in 
phenotypes and their contribution as a member of a group of genes to a particular 
phenotype. Synaptojanin-1 is an inositol phosphatase involved in synaptic vesicle 
recycling and endocytosis via clathrin-coated vesicles (CREMONA et al. 1999). Brains from 
individuals with DS display an increase in the number and size of astrocytes and a high 
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level of synaptojanin-1 expression (ARAI et al. 2002). Few studies have been performed 
in humans in order to understand these relationships, however, due to the inability to 
obtain appropriate tissue samples for these studies, but mouse models are available to 
understand these relationships more conclusively.  
 
1.3 Mouse Models of Down Syndrome 
Mouse models have been used for over a decade to better understand the 
genotype-phenotype correlations in DS. Mice display a high level of homology to 
humans in organ systems and general development, including craniofacial bones (Figure 
1.3). Mice are easily maintained with a high level of tissue access at embryonic stages 
which is not available from individuals with DS. The completion of sequencing for Hsa 21 
(HATTORI et al. 2000) and the mouse genome (WATERSTON et al. 2002) have now provided 
the opportunity to compare sequences of entire chromosomes to determine functional 
relationships of genes (ANTONARAKIS et al. 2004; MURAL et al. 2002)  
Genes found on Hsa 21 are dispersed among three mouse chromosomes, Mmu 
10, 16, and 17, presenting a challenge in engineering a mouse model fully 
representative of the genetic condition of DS, despite the homology between mouse 
and human genomes (Figure 1.4). However, many genes map to these mouse 
chromosomes which are not orthologous to Hsa 21 genes, adding another layer of 
complexity. For example, Hsa 21 genes including Sod1, App, Ets2, and Ifnra/Ifnrb are 
located on distal Mmu 16, but Mmu 16 genes such as the λ light change immunoglobulin 
genes (IGL) and protamine genes (PRM1 and PRM2) are not found on Hsa 21, though 
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they have not been shown to have any involvement in DS pathogenesis (THREADGILL et al. 
1991). The most commonly used mouse model, Ts(1716)65Dn or Ts65Dn, represents a 
triplication of approximately half of the gene orthologs found on Hsa 21 (Figure 1.5). 
The extrachromosomal segment found in this mouse model is comprised of the 
telomeric end of Mmu 16, attached to the centromere and approximately 10 Mb of 
Mmu 17, including the genes corresponding to the 21q21-22.3 region on Hsa 21 
(DAVISSON et al. 1993; REINHOLDT et al. 2011). However, the centromeric portion and 
other gene content of Mmu 17 to which the extrachromsomal segment is attached does 
not map to Hsa 21. The dosage of these genes is currently unknown, introducing an 
extra variable in understanding the role of these Hsa 21 orthologs in Ts65Dn mice 
(DAVISSON et al. 1993; REINHOLDT et al. 2011). The Ts65Dn mouse also contains a 
triplication of the DSCR, once thought to contribute to the primary phenotypes of DS, 
and is the most commonly studied DS mouse model (REEVES et al. 1995).  
This mouse model appears to closely mirror phenotypes of DS, including small 
stature, craniofacial dysmorphology, ID, behavioral abnormalities, impaired integration 
of visual and spatial learning and decreased susceptibility to solid tumor development 
(REEVES et al. 1995; RICHTSMEIER et al. 2000; SUSSAN et al. 2008). Ts65Dn mice are smaller 
than euploid littermates to the point that they appear visually different in body size by 
genotype shortly after birth (CONTESTABILE et al. 2009b; ROPER et al. 2006b). Of particular 
interest, Ts65Dn mice replicate many of the craniofacial features associated with DS, 
including a small, dysmorphic mandible, brachycephaly, and a small midface. A study by 
Richtsmeier and colleagues utilized EDMA, Euclidean Distance Matrix Analysis, to 
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measure three-dimensional coordinate locations of cranial and mandibular landmarks in 
Ts65Dn and euploid mice. The comprehensive results showed that Ts65Dn mice display 
reduced width across the posterior maxilla, shortened to varying degrees in rostro-
caudal dimensions, reduced overall maxillae, and reduced distance along the rostro-
caudal axis of the maxillae, revealing a smaller overall flattened face compared to 
euploid counterparts. In addition, the Ts65Dn neurocranium is reduced in size with 
similar or larger distances along the medio-lateral axis, resulting in a broad, 
brachycephalic phenotype compared to euploid mice. Furthermore, 97% of the linear 
distances analyzed using mandibular landmarks were smaller in Ts65Dn mice than 
euploid mice (RICHTSMEIER et al. 2000). These phenotypes are highly representative of DS 
craniofacial alterations and are even representative of the high level of variability in 
craniofacial phenotypes that individuals with DS often display (RICHTSMEIER et al. 2000).  
Ts65Dn mice display alterations in bone mineral density and strength (BLAZEK et 
al. 2011), in line with the low bone mineral content found in adults, adolescents, and 
children with DS (BAPTISTA et al. 2005; GONZALEZ-AGUERO et al. 2011). Ts65Dn neonates 
display cardiac anomalies which lead to subsequent mortality (MOORE 2006), including 
anomalies of the aortic arches in neonates which appear similar to those of neonates 
with DS (CHAOUI et al. 2005; MCELHINNEY et al. 2002). The incidence of gross cardiac 
vascular abnormalities is only 17% in Ts65Dn neonates, however, compared to 50% of 
individuals with DS having congenital heart defects and differences are present in the 
anomalies themselves (FREEMAN et al. 1998; WESSELS et al. 2003; WILLIAMS et al. 2008). 
Interestingly, Ts65Dn neonates do not display the severe phenotype of complete 
12 
 
1
2 
atrioventricular canal abnormality as in individuals with DS and many differences exist in 
other less common abnormalities between Ts65Dn and DS neonates (WILLIAMS et al. 
2008). Phenotypically, the structure and function of the Ts65Dn brain has been 
extensively studied. Ts65Dn mice display reduced long term potentiation (LTP), deficits 
in novel object recognition, learning, and memory, and a smaller overall brain volume 
(ALDRIDGE et al. 2007; BELICHENKO et al. 2009; ESCORIHUELA et al. 1998). Interestingly, 
Ts65Dn mice have also been successfully used to predict phenotypes in individuals with 
DS which have not previously been identified. In a study by Baxter and colleagues, 
Ts65Dn mice were found to have a reduction in granule cell density in the cerebellum—
a phenotype later investigated and confirmed in the DS cerebellum (BAXTER et al. 2000).  
Many other mouse models of DS have been developed that represent different 
partial trisomies for mouse orthologs of Hsa 21 (Figure 1.5). The Ts1Rhr mouse model 
containing a triplication of the 33 orthologs including those between Cbr3 and Mx2 
which (comprising the DSCR) was developed to better understand the contribution of 
this region to major DS phenotypes (OLSON et al. 2007). Interestingly, when the Ts1Rhr 
mouse model was created and craniofacial morphology assessed, the mandible was 
found to be larger in Ts1Rhr mice compared to euploid littermates and thus the DSCR 
was found to be insufficient in producing DS-like facial phenotypes (OLSON et al. 2004a). 
Furthermore, Ts65Dn mice containing monosomy for the DSCR showed measurements 
of the mandible similar to those in Ts65Dn, indicating that the DSCR is largely 
unnecessary for this phenotype (OLSON et al. 2004a). Additional studies, though altered 
slightly in methodology, have been inconclusive as to the contribution of this region to 
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brain phenotypes in Ts1Rhr mice (BELICHENKO et al. 2009; OLSON et al. 2007). While the 
Ts1Rhr mouse model does represent a number of genes thought to be involved in a 
number of DS phenotypes and can be used extensively to understand the role of a 
specific subset of genes in DS phenotypes, it does not definitively model all phenotypic 
aspects of the disorder. Furthermore, allelic differences identified when studying mice 
and embryos from the Ts1Rhr line on two genetically different backgrounds revealed 
alterations in embryonic phenotypes (embryonic and mandibular precursor size) and 
postnatal weight, litter size, and transmission of the trisomy (DEITZ and ROPER 2011). 
These allelic differences are important to keep in mind when comparing studies using 
the same mouse model as well as studies across mouse models. 
Several other segmentally trisomic mice have been developed to better 
understand candidate genes and regions, as well as the contributions of genetic material 
from one chromosome versus another (Figure 1.5). For example, the Tc1 mouse is 
transchromosomic—it contains not only its normal complement of genes, but also an 
engineered chromosome containing multiple Hsa 21 regions (approximately 92% of all 
known Hsa 21 genes), reflecting more closely the dosage difference present between 
trisomic and normosomic individuals (O'DOHERTY et al. 2005). Tc1 mice display reduced 
LTP, a mild learning impairment, tendency toward hyperactivity, and failure of fusion 
between the ventricular septum and proximal outflow tract cushions of the heart 
compared to euploid littermates and in line with DS phenotypes (O'DOHERTY et al. 2005). 
Interestingly, Tc1 mice show no alterations in craniofacial development (O'DOHERTY et al. 
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2005). It is important to note, however, that these mice are mosaic for the Trisomy and 
this mosaicism varies among mice and tissues (DAS and REEVES 2011). 
In addition, the Ts1Cje, a segmentally trisomic mouse for Hunk to Zfp295 or 
approximately 81 Hsa 21 orthologs, displays some, but not all DS phenotypes, though 
they show many parallels to Ts65Dn phenotypes (SAGO et al. 1998). For example, Ts1Cje 
mice display learning and memory impairment, behavioral abnormalities indicative of 
hippocampal dysfunction, and reduced LTP, though several of these phenotypes appear 
to be less severe than in Ts65Dn mice (BELICHENKO et al. 2009; OLSON et al. 2007; SAGO et 
al. 1998; SIAREY et al. 2005). Furthermore, Ts1Cje display craniofacial alterations similar 
to those in Ts65Dn mice and individuals with DS, with the exception of brachycephaly 
(RICHTSMEIER et al. 2002). Interestingly, though Ts1Cje mice display significantly reduced 
cerebellar volume (similar to Ts65Dn), showed little change in granule cell and Purkinje 
cell density, indicating a significant alteration in phenotype compared to Ts65Dn and a 
role for triplicated genes dissimilar between the two models (OLSON et al. 2004b).  
Ts1Yey, Ts2Yey, and Ts3Yey are three other mouse models which have been 
developed to test the effects of triplication of Hsa 21 orthologs in three copies in the 
mouse. Ts1Yey, Ts2Yey, and Ts3Yey mice are trisomic for Has 21 gene orthologs found 
on Mmu 16, Mmu 10, and Mmu17, respectively (YU et al. 2010a). Ts1Yey and Ts3Yey 
mice display some learning impairment (YU et al. 2010b). Ts2Yey mice, however, do not 
display alterations in learning or memory (YU et al. 2010a). A combination of these three 
models called the ‘triple trisomy’ model (Ts1Yey;Ts2Yey;Ts3Yey) mimics most behavioral 
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phenotypes also observed in Ts65Dn mice (YU et al. 2010a). Further research is 
necessary to better classify these models and their genotype-phenotype relationships. 
The Ts1Yah mouse model contains a triplication of 12 genes from Abcg1-U2af1 
found in the Hsa 21 sub-telomeric region and was developed to understand what, if any, 
contribution these genes make to DS phenotypes. Ts1Yah mice display defects in novel 
object recognition, open field, and Y-maze tests. However, these mice show improved 
hippocampal-dependent spatial memory and enhanced LTP in the hippocampus, with 
several genes including Ndufv3, Wdr4, Pknox1, and Cbs, all candidates for the gain in 
cognitive function when overexpressed (PEREIRA et al. 2009). As described, segmentally 
trisomic mouse models have added significant information to the field which helps 
describe how the genes found in these segments contribute to various phenotypes.  
 
1.4 Mouse Genotype-Phenotype Relationships 
Mice have been readily used for over a decade in DS to better understand how 
trisomic genes impact the development of phenotypes, allowing for accessibility to 
numerous tissues and all stages of development. In particular, using models trisomic or 
monosomic for a single gene, or using knock-in and knockout approaches have made DS 
mouse models even more valuable to the research community. Genes such as that 
encoding amyloid precursor protein (APP) have been heavily studied for their 
contribution to DS phenotypes including the development of Alzheimer disease (AD)-like 
pathology in all individuals trisomic for this gene. Ts65Dn mice display cognitive deficits 
in the Morris water maze, cholinergic neuronal degeneration, and decreased nerve 
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growth factor (NGF) transport, all related to changes in the hippocampus—a major 
target of AD pathological insults (SALEHI et al. 2006; SEO and ISACSON 2005). Using mice 
generated from a cross of Ts65Dn mice females (three copies of App) with males with 
just one copy of App (a single copy deletion), investigators found that offspring were 
viable with no detectable nervous system abnormalities (CATALDO et al. 2003). 
Furthermore, while Ts65Dn mice with three copies of App have decreased NGF 
transport, knock down of one copy of App dramatically increased NGF transport, 
cultivating a direct relationship between copy number of App and NGF retrograde 
transport in Ts65Dn mice (SALEHI et al. 2007). 
Brains from Ts65Dn mice display an increase in the number and size of 
astrocytes and a high level of synaptojanin-1 expression (ANTONARAKIS et al. 2004). 
Interestingly, Ts65Dn mice disomic for Synj1 (Synj1 knockout mice) display smaller 
brains than euploid littermates, postnatally, at a time when gliogenesis is prominent, 
thus indicating a potential astroglial population may cause this decreased brain size 
(HERRERA et al. 2009). Recently, Herrera and colleagues explored this interaction in vivo 
and found that in Synj1 knockout mouse brains, glial markers were down regulated 
compared to euploids, but no changes in neuronal markers, indicating that Synj1 is 
involved in astrogliogenesis but not neurogenesis (HERRERA et al. 2009). Interestingly, 
synaptic morphology and endocytosis, appear to be regulated by multiple genes, 
including Synj1 as well as Itsn1 and Rcan1. A recent study investigated the effects of 
these three genes on the altered synapses and endocytosis seen as a DS neuronal 
phenotype. Investigators found that overexpression of each gene individually in the 
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context of a normal genetic complement did lead to abnormal synapses, but 
overexpression of all three genes in the context of a normal genetic complement were 
necessary in order to cause the full phenotype of impaired vesicular recycling with 
regulation of genes by other genes within this group of three (CHANG and MIN 2009). 
 
1.5 Dyrk1a: a Candidate Gene for Craniofacial Development Regulation 
Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A, DYRK1A , a 
gene mapped to 21q22.13 and triplicated in the Ts65Dn and Ts1Rhr mouse models, is a 
serine-threonine kinase and a homolog of the Drosophila minibrain (Mnb) gene, known 
to be involved in neuronal proliferation and postembryonic neurogenesis (TEJEDOR et al. 
1995). Dyrk1a is known to phosphorylate several transcription factors including Nfat 
(nuclear factor of activated T cells) in mouse cortical neurons and RNAi studies in 
Drosophila, and the forkhead transcription factor FKHR in HEK-293 cells (ARRON et al. 
2006; GWACK et al. 2006; WOODS et al. 2001), giving it the potential to impact various 
cellular events (Figure 1.6A) and is also capable of self-phosphorylation at its kinase 
domain (KENTRUP et al. 1996). In addition, DYRK1A is hypothesized to act in concert with 
another Hsa 21 gene, RCAN1, a calcineurin inhibitor (Figure 1.6B), in the localization of 
the transcription factor NFAT (ARRON et al. 2006; EPSTEIN 2006). This transcription factor 
plays a role in lymphoid development, morphogenesis of the vertebrate heart valves, 
vascular organization, brain development and skeletal development and homeostasis 
(GRAEF et al. 2001; SITARA and ALIPRANTIS 2010; WINSLOW et al. 2006).  
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Mutations in this gene have been reported to lead to reduced optic lobes and 
central brain hemispheres in adult Drosophila (SMITH et al. 1997), and its overexpression 
has been linked to DS pathophysiology of Alzheimer disease (KIMURA et al. 2007; RYOO et 
al. 2007). In vitro, Dyrk1a is known to induce phosphorylation of p53 and inhibits 
proliferation of embryonic neural cells (PARK et al. 2010), while overexpression of Dyrk1a 
inhibits proliferation and induces premature neural differentiation of neural progenitor 
cells (YABUT et al. 2010), lending to the suggesting of Dyrk1a as a strong candidate for 
neurological abnormalities in DS. In addition, knockout mice for Dyrk1a are embryonic 
lethal and Dyrk1a heterozygotes exhibit developmental delay and decreased viability, 
indicating an effect of gene dosage (FOTAKI et al. 2002). Expression patterns have been 
sparingly defined throughout the adult and developing brain in mice (HAMMERLE et al. 
2002; SMITH et al. 1997) and heart in rats (OKUI et al. 1999), but the actual role of Dyrk1a 
in many of these cases remains to be elucidated. 
Mice carrying deletions of components of the NFAT pathway share similar skull 
and facial phenotypes to those of DS (ARRON et al. 2006). Regulation of this pathway is 
modulated by several components: calcium is responsible for stimulating calcineurin, a 
phosphatase, which binds directly to NFATc (also known as NFAT2) proteins leading to 
dephosphorylation and nuclear translocation of NFATc (BEALS et al. 1997); DSCR1/RCAN1 
endogenously inhibits the binding of calcineurin to NFAT, preventing its calcineurin from 
dephosphorylating NFAT and allowing its nuclear translocation (FUENTES et al. 2000); and 
DYRK1A primes substrates for phosphorylation by GSK3, which then phosphorylates 
NFATc proteins in the nucleus, leading to translocation to the cytoplasm (BEALS et al. 
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1997; GRAEF et al. 2001). Thus, it has been hypothesized that, in the cases of DS 
compared to individuals with a normal genetic complement, three copies rather than 
two of DYRK1A and RCAN1 would lead to a synergistic effect on NFAT by causing high 
levels of cytoplasmic localization of NFAT when compared to its homeostatic state 
(ARRON et al. 2006) (Figure 1.7). 
 Of particular interest in this pathway is how DYRK1A and RCAN1 are regulated 
both independently and in the presence of one another. Recently, Dyrk1a was found to 
directly interact and phosphorylate Rcan1, which in turn leads to the priming of Gsk3β 
and further Rcan1 phosphorylation. This phosphorylation was also shown to inhibit the 
phosphatase activity of calcineurin, leading to reduced Nfat nuclear localization and 
thus transcriptional activity (JUNG et al. 2011). Both of these genes are triplicated in DS 
and the Ts65Dn and Ts1Rhr mouse models of DS and are found in the DSCR. From this 
information, it can thus be hypothesized that these genes would maintain a relative 1.5 
fold expression to euploid tissue if no other factors are involved. Therefore, due to the 
inhibitory actions of both Dyrk1a and Rcan1, a feedback loop in which both Dyrk1a and 
Rcan1 are expressed approximately 1.5 fold in a tissue would occur, leading to 
cytoplasmic Nfat. Furthermore, a study in bone homeostasis showed that forced 
expression of NFATc1 induced DYRK1A expression, suggesting a negative feedback loop 
which regulates NFAT activity (LEE et al. 2009). If this paradigm holds true 
temperospatially, then cycling of Dyrk1a levels, as Dyrk1a is a downstream target of 
Nfat activation, would hypothetically lead to increased activation of Rcan1 in the 
presence of excess Dyrk1a and thus increased cytoplasmic localization of Nfat. 
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1.6 Craniofacial Development 
All individuals with DS are known to display a form of craniofacial phenotypes 
through which they are often first classified at birth. Though not typically used as a fetal 
marker of DS, it has been hypothesized that a shortened mandible may be 
representative of the craniofacial anomalies associated with DS as a prenatal marker, 
especially considering the secondary phenotypes which arise, characterizing the 
syndrome. The craniofacial skeleton is affected extensively, leading to the adverse 
phenotypes which impact quality of life and independence for these individuals. 
Craniofacial alterations most commonly associated with DS include both skeletal 
anomalies and alterations in soft tissue. The characteristic facial bone alterations span 
the architecture of the skull and include a shortened midface, small, dysmorphic 
mandible, small oral cavity, relative macroglossia, and brachycephaly (a decrease in the 
distance from the anterior to the posterior of the skull) (GUIHARD-COSTA et al. 2006; 
GUIMARAES et al. 2008). In conjunction with skeletal abnormalities, soft tissue alterations 
including upslanting palpebral fissures, inner epicanthic folds, and a generalized 
hypotonia compound problems which arise from these primary features (EPSTEIN 2001). 
Due to these alterations, secondary phenotypes are often noted clinically and include 
both structural and functional complications. Many individuals with DS present with 
impaired mastication and speech, narrow airways, airway and esophageal obstructions, 
dental anomalies and sleep apnea that appear to be comorbid with Down syndrome 
(SHOTT 2006; VENAIL et al. 2004). Of consequence is the interaction between tissues in 
the region of the developing skull and face and thus, alterations in this process due to 
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changes set in place from Trisomy 21 may cause a gross effect on multiple features of 
the DS skull and face (HELMS and SCHNEIDER 2003; KNIGHT and SCHILLING 2006). 
 The development of the craniofacial skeleton is a complex process mediated by 
the interactions of several tissues. The embryonic precursor to the mandible, the first 
pharyngeal arch, or PA1, develops from cells migrating primarily from rhombomere 2 
(mandibular component) and rhombomere 1 and the caudal mesencephalon (maxillary 
component) (LUMSDEN et al. 1991). Cells populating the PA1 consist of cranial neural 
crest cells (NCC), a migratory population of cells which undergoes epithelial-to-
mesenchymal transition (EMT) in order to delaminate from the closing dorsal neural 
folds in mammals (ACLOQUE et al. 2009). These cells are known to sculpt the 
development of the facial prominences and the pharyngeal arches through their 
contributions to the connective tissues of the face and the development of the facial 
skeleton (CORDERO et al. 2010) and in essence lay the scaffold upon which the head and 
face become constructed, thus implicating them in the morphology of the face (TRAINOR 
2010). Cranial NCC contribute not only to the development of bone and cartilage of the 
head, but also to connective tissue and peripheral nervous tissue (SANTAGATI and RIJLI 
2003). Furthermore, other populations of NCC play vital roles in the development of 
specific cell types in the peripheral nervous system, including glial cells and neurons, 
melanocytes, dental pulp and dentin, cardiac tissue, and smooth muscle lining (DUPIN 
and SOMMER 2012). This particular subset of cell, however, when it interacts with surface 
ectoderm, mesoderm, and pharyngeal endoderm, contributes to the proper 
development of the PA1 derivatives, including the mandible (COULY et al. 2002).  
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Due to the contributions of these cells to the structures of the head and neck, 
alterations in the characteristics of these cells including their migratory patterns and 
proliferative capacities provide a potential basis for anomalies occurring in these areas, 
and thus it has been hypothesized that a common mechanism affecting these cells is 
caused by overexpression of Hsa 21 genes (KIRBY 1991). Similar pathologies also seen in 
Treacher Collins syndrome of cranial NCC origin in which individuals develop hypoplasia 
of facial bones including the maxilla and mandible, and alterations of the external and 
inner ears, leading to secondary phenotypes of malocclusion and conductive hearing 
loss (PHELPS et al. 1981; POSWILLO 1975). Interestingly, these individuals also display 
alterations in brain development reminiscent of those seen in DS (TEBER et al. 2004). 
It is important to note that NCC have been associated with a number of 
congenital anomalies which are not limited to the craniofacial region, but often occur 
comorbidly with craniofacial alterations. For example, individuals with Di George 
Syndrome display craniofacial alterations, but also thyroid, parathyroid, thymus, and 
heart/vessel anomalies which have some relation to NCC origin (KIRBY and STEWART 1984). 
In addition, individuals with Noonan’s Syndrome also display craniofacial alterations 
which are in conjunction with heart/vessel anomalies (NOONAN 1968).  
Several hallmarks of cranial NCC location and activity mark the timeline of PA1 
development. At stage 10 on the Carnegie Scale of Development (approximately 3 
weeks in humans and 8.25 days in mice), the neural folds from which the cranial NCC 
delaminate begin to fuse. By stage 11 (approximately 3.5 weeks in humans and 9-9.25 
days in mice) the PA1 has begun to form and cranial NCC continue to migrate through 
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the body to various structures which will contribute to the head and neck. By stage 13 (4 
weeks in humans and 9.5 days in mice), nearly all migration of cranial NCC from the NT 
and neural folds to the PA1 has completed and those cells within the PA1 continue to 
undergo mitosis (O'RAHILLY and MULLER 2007; YAMAGISHI et al. 2006). The PA1, once fully 
developed, continues to delineate into a number of structures which will become more 
evident with maturation. For example, tissue from the PA1 will contribute not only to 
the mandible, but also to tissues of the skull wall, the teeth, the middle ear, part of the 
tongue, and many other soft tissues of the orofacial region (YAMAGISHI et al. 2006). Due 
to the phenotypes observed in individuals with DS including craniofacial development, 
the cranial NCC population has been studied to understand the mechanisms behind DS 
craniofacial phenotypes, especially through the use of DS mouse models.  
 
1.7 Cellular Phenotypes of Down Syndrome 
Of particular interest in understanding how DS phenotypes arise during 
development are the cellular phenotypes of individuals with DS. As previously described, 
a cranial NCC deficit is present in the developing mandible of Ts65Dn embryos which 
appear to be caused by the observed proliferation and/or migration deficits from in vitro 
studies (ROPER et al. 2009). This deficit has been classified between E9.25 during which 
no significant alterations in PA1, NCC number, or migration appear to be present, and 
E9.5 where these alterations become evident quantitatively (ROPER et al. 2009). In 
essence, this creates a window of 6 hours during which the deficit develops and 
precisely defines a period of time crucial for further study. Furthermore, it is important 
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to note that this cellular phenotype has been classified in vitro using neural tube 
explants and cresyl-violet stained embryo sections, which showed a decreased 
propensity of cells delaminating from the neural tube to migrate and proliferate, 
respectively, in Ts65Dn embryos compared to euploid embryos (ROPER et al. 2009). 
Other studies have described cellular proliferation deficits in vitro using cells 
derived from individuals with DS including the fetal cerebellum, hippocampus, and skin 
fibroblasts (CONTESTABILE et al. 2007; GUIDI et al. 2011; KIMURA et al. 2005). Using cells 
from the hippocampal dentate gyrus from fetuses with DS and Ts65Dn mice, 
investigators showed that a reduction in the number of proliferating cells occurred 
compared to euploid controls, marked by a reduction of cells cycling in S phase, but an 
increase in proliferating cells in G2 (CONTESTABILE et al. 2007). This study not only better 
classified the hypothesized proliferation impairment, but also suggested a role for 
alterations in the cell cycle as a determinate of cell proliferation propensity (CONTESTABILE 
et al. 2007). Ts65Dn mice also display other cellular deficits, but these have been 
primarily limited to neurogenesis and a proliferation deficit in neural and granule 
precursor cells shown through in vitro studies (CONTESTABILE et al. 2009a; TRAZZI et al. 
2011). Additionally, neuronal precursors of the cerebellum and hippocampus have been 
shown to exhibit reduced proliferation rather than apoptosis as previously hypothesized 
(CHAKRABARTI et al. 2007; CONTESTABILE et al. 2007; LORENZI and REEVES 2006; ROPER and 
REEVES 2006). In order to understand overall proliferation of cells in DS, Contestabile and 
colleagues also evaluated proliferation in peripheral tissues of Ts65Dn neonates in vivo 
and in vitro and found a proliferation impairment in cultured fibroblasts, characterized 
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by fewer actively proliferating cells but no observed change in the cell cycle 
(CONTESTABILE et al. 2009b). This study emphasized that potential for an overall defective 
proliferation mechanism as a phenotype of DS as inferred from results using Ts65Dn-
derived tissue (CONTESTABILE et al. 2009b). Interestingly, Tc1 fibroblasts also showed DS-
like aberrant proliferation and adhesion, as well as a decreased cell migration 
propensity in vitro (DELOM et al. 2009), further solidifying the hypothesis of a generalized 
proliferation deficit in DS tissues. 
 
1.8 Treatments in Down Syndrome 
 The focus on therapeutic interventions in DS has primarily been dedicated 
toward rescuing cognitive deficits in individuals with DS with much emphasis being place 
on specific gene targets with a phenotype of interest in mind. Several pharmacological 
therapeutics have since been proposed to overcome, for example, cellular proliferative 
deficits, in hopes of rescuing cognitive deficits in DS mouse models. However, little has 
been done to understand the mechanism of this deficit and ameliorate other cellular 
deficiencies, such as that of the mandibular precursor during developing. Several studies 
have pioneered these treatments in DS mouse models, including the use of several 
drugs which effect synaptic plasticity, brain biochemistry, and brain morphology. LTP is 
reduced in the hippocampus of Ts65Dn mice and occurs in part due to an imbalance 
between excitatory and inhibitory activity which can be overcome by drugs that inhibit 
γ-aminobutyric acid A (GABAA) receptors (BELICHENKO et al. 2007; KLESCHEVNIKOV et al. 
2004; SIAREY et al. 1997). Picrotoxin (PTX) and pentyletonetetrazol (PTZ) bind non-
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competitively to GABAA receptors acting as antagonists. Studies in Ts65Dn mice treated 
with PTX or PTZ have revealed complete rescue of novel object recognition test deficits 
and rescue of learning and memory deficits even after cessation of treatment (FERNANDEZ 
and GARNER 2007; RUEDA et al. 2008) compared to untreated Ts65Dn mice. Clinical trials 
are currently underway to understand the impacts of PTX and PTZ in humans.  
 Memantine, an NMDA receptor antagonist, is currently approved as a treatment 
for moderate to severe AD as it has been routinely shown to lessen cognitive 
deterioration through a neuroprotective function, with benefits discernible in cognition, 
function, and global scale measurements over long-term treatment (AREOSA and SHERRIFF 
2003). Several groups have thus moved this treatment into the Ts65Dn mouse model of 
DS in short and long term studies and assessed its effects on memory and degeneration, 
two phenotypes well-classified in Ts65Dn mice (COSTA et al. 2008; LOCKROW et al. 2011; 
RUEDA et al. 2010; SCOTT-MCKEAN and COSTA 2011). Memantine treatment was sufficient 
to improve both spatial and recognition memory performance in Ts65Dn mice, but no 
morphological changes were observed in the treated mice. Interestingly, treated mice 
showed elevated levels of brain-derived neurotrophic factor expression in the 
hippocampus and frontal cortex, indicating that behavioral modification may be a result 
of memantine treatment (LOCKROW et al. 2011; RUEDA et al. 2010). Clinical trials are also 
underway for mematine treatment to understand its efficacy in humans. 
 Decreased NGF transport has been observed in Ts65Dn hippocampi and models 
AD pathology. An increase of amyloid-β peptide, a hallmark of AD, also occurs after 
traumatic brain injury (TBI), leading to an increased risk for AD later in life. NGF has 
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recently been shown to display trophic properties which produce an anti-amyloidogenic 
activity (CALISSANO et al. 2010) and thus may have a role in the treatment of AD 
pathology. Mice with induced TBI showed significantly increased APP and Aβ expression, 
but those treated with NGF intranasally showed attenuated Aβ deposition and improved 
functional outcomes (TIAN et al. 2012). Thus, NGF appears to be an excellent candidate 
in treatment of AD pathology after initial disease development and would be ideal for 
study in the Ts65Dn mice. Similarly, L-DOPS corrects deficiencies in norepinephrine 
found previously in Ts65Dn mice and, in combination with carbidopa, restores learning 
and memory deficits according to contextual fear conditioning tests (SALEHI et al. 2009). 
 The small, cellular deficit in the cerebellum of individuals with DS is of concern 
due to the importance of this structure in motor control and various cognitive tasks. A 
study to understand the origin of this deficit in the Ts65Dn mouse revealed a paucity of 
granule cell precursors early in postnatal development. Interestingly, these cells showed 
a marked reduction in sonic hedgehog (Shh) protein signaling mitogenic response. 
Treatment of newborn trisomic mice with a Shh agonist led to a restoration of granule 
cell precursors and mitotic cells in the cerebellum to euploid levels. Results from this 
study not only indicate that this cellular deficit results from defective response to Shh, 
but also shows that an agonist for Shh can jumpstart pathways necessary to rescue the 
cellular deficit, linking Shh spatiotemporally to mitosis of these cells (ROPER et al. 2006a). 
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1.9 Inhibitors of Dyrk1a as Treatment in Down Syndrome 
There has been a heavy focus on therapies utilizing the inhibition of DYRK1A, due 
to its complex involvement in DS phenotypes in recent years. Epigallocatechin-3-gallate 
(EGCG) is the most common polyphenol in green tea, constituting 9-13% of the total dry 
weight (DUFRESNE and FARNWORTH 2001) and recognized worldwide for its antioxidant 
properties and other health benefits including positive effects on metabolic syndrome, 
cognitive function, neuroprotection, cancers, bone health, cardiovascular risk reduction, 
and many others (Figure 1.8A) (HODGSON and CROFT 2010; NAGLE et al. 2006; WILLIAMSON 
et al. 2011). EGCG and many similar components have been well researched and 
categorized for their use as therapeutics in human cancer prevention in treatment 
through their ability to decrease angiogenesis and their anti-proliferation effects as well 
as their ability to prevent oxidative damage in healthy cells (CHEN et al. 2011). Green tea 
polyphenols also maintain several categories of effectors, most notably including 
receptor tyrosine kinases (RTKs) and gene targets, including Dyrk1a (BAIN et al. 2007; 
LARSEN et al. 2010), and these compounds appear to affect a wide array of signal 
transduction pathways downstream including JAK/STAT, MAPK, PI3K/AKT, Wnt, and 
Notch (SINGH et al. 2011). The inhibition of RTKs is especially relevant, since RTKS play a 
crucial role in the homeostasis of cellular processes, including cell proliferation and 
apoptosis (LARSEN et al. 2010). Furthermore, since EGCG is able to cross the blood-brain 
and placental barriers (CHU et al. 2007) and is already currently available for oral 
administration at a reasonable cost (SARTIPPOUR et al. 2002), the use of this compound 
during embryonic development, when many of the known deficits in DS are 
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hypothesized to arise neurologically and otherwise (such as the mandibular precursor), 
is feasible. Similarly, since Dyrk1a is found in three copies in DS and in multiple mouse 
models of DS at specified times points and tissues (such as the E9.5 PA1 or the DS brain), 
its use for both in vitro, for the determination of efficacy, viability, and a general 
understanding of adverse effects, and in vivo studies to determine the effects of Dyrk1a 
on these phenotypes by reducing only Dyrk1a copy number in an otherwise segmentally 
trisomic system, could potentially be therapeutic. 
Several in vitro studies using cells from cell lines and mice and in vivo studies in 
mice have been performed to date outlining the wide array of roles EGCG can play in 
the disease pathophysiology. Nude mice treated with EGCG through oral gavage in the 
presence of a adjuvant led to inhibition of tumor growth and delayed tumor progression 
through increased apoptosis, decreased proliferation, and reduced phosphorylation of 
AKT (ZHANG et al. 2008). Mice transgenic for Dyrk1a and four other genes fed a diet of 
green tea polyphenols showed a rescue of brain weight alterations and cognitive deficits 
observed before treatment, indicating not only the importance of Dyrk1a in these 
phenotypes, but also the translational impact of EGCG in vivo (GUEDJ et al. 2009).  
Little evidence currently exists in the literature regarding these properties in 
humans, but several recent studies have described some positive effects with no 
significant adverse side effects noted in all studies. A study conducted by Ellinger and 
colleagues reveled increased plasma antioxidant capacity, reduction of oxidative stress 
markers, and reduced lipid peroxidation in individuals on various EGCG and green tea 
polyphenol regimens (ELLINGER et al. 2011). In addition, Polyphenon E, a standardized 
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green tea polyphenol pharmaceutical, is currently being used in clinical trials for 
prostate and bladder cancer, as well as leukemia, (HARA 2011; SHANAFELT et al. 2009) and 
has been approved by the FDA for other uses, such as a treatment for warts (TATTI et al. 
2010), and developments continue to be made in the hope of producing more specific 
compounds for clinical trials (HARA 2011). 
Harmine, a β-carboline alkaloid derived from plants, is another natural Dyrk1a 
inhibitor which targets the kinase activity of this receptor tyrosine kinase (Figure 1.8B) 
(BAIN et al. 2007; GOCKLER et al. 2009). In vitro studies using harmine as a Dyrk1a 
inhibitor have shown its ability to inhibit tau phosphorylation at Alzheimer disease-
relevant sites and regulate NFAT expression in osteoclast progenitor cells (EGUSA et al. 
2011; FROST et al. 2011). However, harmine inhibits monoamine oxidase A and could 
lead to a build up on neurotransmitters in the brain (BOEIRA et al. 2001). 
 INDY, a benzothiazole derivative which has Dyrk1a ATP-competitive binding 
affinity, is capable of reversing aberrant tau phosphorylation (an Alzheimer disease 
phenotype) in culture and is sufficient to rescue levels of repressed NFAT signaling 
induced by Dyrk1a overexpression (Figure 1.8C) (OGAWA et al. 2010). Further studies 
using the pro form of this drug will be necessary to understand its efficacy in vivo.  
 A study performed by Wang and colleagues showed the importance of screening 
compounds for their confirmation and interaction with the ATP binding pocket of 
DYRK1A, shown to be the target of other potent DYRK1A inhibitors and an optimal site 
for inhibition (ADAYEV et al. 2006; ADAYEV et al. 2011). The screening revealed six novel 
compounds, of which two were selected (compounds 3 and 5) for studies to elucidate 
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their mechanism (Figures 1.8 and 1.8E). Compounds 3 and 5 displayed similar 
confirmations to INDY and harmine, respectively, likely accounting for their potency, 
with compound 3 providing stronger inhibition than EGCG in vitro (WANG et al. 2012). 
 
1.10 Hypotheses 
 We hypothesize that the NCC deficit found in Ts65Dn embryos in vitro and in vivo 
can be reproduced and refined in our cell culture system and modified using natural 
Dyrk1a inhibitors to rescue proliferation and migration deficits to euploid levels. We also 
hypothesize that harmine and EGCG work by independent mechanisms , though both 
involve inhibition of Dyrk1a, due to their known impacts in similar and dissimilar 
biochemical pathways and activities. Furthermore, we hypothesize that in vivo 
treatment of Ts65Dn pregnant mother with EGCG will lead to a rescue of the trisomic 
embryonic mandibular precursor to euploid volume and cell number. 
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CHAPTER 2. MATERIALS AND METHODS 
2.1 Mouse Husbandry 
Female B6EiC3 Sn a/A-TS(1716)65Dn (Ts65Dn) and male B6C3F1 mice obtained 
from The Jackson Laboratory (Bar Harbor, Me) were mated in breeding colonies at 
Indiana University-Purdue University Indianapolis to produce female offspring for colony 
maintenance and for breeding to complete embryonic studies described below. Female 
Ts65Dn mice were bred with Wnt1-lac Z males (B6CBA-Tg(Wnt1-lacZ)206Amc/J (The 
Jackson Laboratory, Bar Harbor, ME) for embryonic studies. Females were checked for 
estrus and placed in the cage containing the Wnt1-lacZ male for overnight mating. 
Females were checked for vaginal plugs the next morning to ascertain timed mating. 
Noon on the day of the plug was established as embryonic day 0.5 (E0.5) for developing 
embryos. Pregnant females were isolated from breeding partners until they were killed 
when embryos were at developmental stage E9.5. Pregnant mothers were euthanized 
between 10am and 12pm nine days after the plug was found with isoflurane (Vedco, 
Inc., St. Joseph, MO), followed by cervical dislocation. Embryos were dissected from 
pregnant females and were assessed for developmental stage by somite number. 
Somites are collections of mesoderm which have the ability to differentiate into 
numerous tissue types throughout the body, including cartilage, bone, muscle, and 
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dermis (CHRIST and ORDAHL 1995) and have recently been shown to act as a staging 
measurement of intrinsic development (VENTERS et al. 2008), though they have been 
utilized for developmental staging extensively (PALMEIRIM et al. 2008). Dissected embryos 
were then fixed for histological analysis as described below or first pharyngeal arch (PA1) 
and neural tube (NT) tissues were isolated for further manipulation. Quantification of 
somites was undertaken for each embryo in order to determine their relative 
developmental stage. E9.25 embryos from pregnant females killed at approximately 
6am nine days after the plug were utilized for RNA from the PA1 and NT if between 
somite stages 15 and 18, and E9.5 embryos were utilized for RNA, cell culture, or whole 
mount embryo embedding if between somites stages 21 and 24.  
 Dp(16Cbr1-ORF9)1Rhr (Ts1Rhr) mice were obtained from Dr. Roger Reeves at 
The Johns Hopkins University School of Medicine (Baltimore, MD). These mice had been 
backcrossed toC57BL/6J (B6) mice for 12 generations (N12) to establish the B6.Ts1Rhr 
line. Females were bred with Wnt1-lacZ mice and checked for pregnancy as described 
above. Embryos taken from mothers killed nine days after the plug was found on E9.5 
were utilized for cell culture as described in section. 
  
2.2 Mouse and Embryo Genotyping 
Embryos utilized for this study were genotyped by PCR or fluorescence in situ 
hybridization (FISH). Molecular probes created from BAC clones 401C2 and 433G17 
were utilized in this study (MOORE et al. 1999) as they bind to the distal portion on 
Mmu16 triplicated in the Ts65Dn mouse model. Yolk sacs dropped onto slides were 
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incubated in pre-warmed saline-sodium citrate buffer (SSC, 175.3 g NaCl and 88.2 g 
sodium citrate in 800 ml of H2O, pH 7.0) at 37˚ C for 30 minutes. After incubation, slides 
were passed through an ethanol wash for the purpose of dehydration. Slides were 
washed in cold 70%, 85%, and 100% ethanol for two minutes each, respectively. 
Concomitantly, Denhyb (Insitus Biotechnologies, Albuquerque, NM) was removed from -
20˚ C and allowed to warm to room temperature. Upon reaching room temperature, 
Denhyb was mixed with BAC probes at a 10:1 dilution ratio and heated to 37˚C in a dark 
water bath. Upon removal from the final ethanol wash, slides were warmed on a 37˚C 
dry bath for 3 minutes in a dark room. After warming, 7 µl of the Denhyb:probe 10:1 
mixture was added to the center of each slide. Each slide was then cover slipped with an 
18 x 18 mm glass cover slip and each slip was sealed to the slide using rubber cement. 
Upon sealing, slides were transferred to a pre-warmed 85˚ C dry bath for 5 minutes and 
covered to ensure no light penetration. After incubation, slides were quickly transferred 
to a pre-warmed (37˚ C) humidified chamber to incubate overnight. 
 One day later, rubber cement was removed from each slide in a darkened room 
and slides were incubated in 68˚ C pre-warmed 2X SSC for 5 minutes. Slides were then 
transferred to room temperature 2X SSC for 7 minutes to equilibrate. Simultaneously, 
DAPI (Chemicon International, Temecula, CA) was warmed to room temperature. After 
the equilibrating incubation, 8 µl of Antifade/DAPI was added to the center of each slide 
and each slide was covered with a 22 x 22 mm glass cover slip. Slides were viewed 
immediately on a Nikon Eclipse 80i microscope using fluorescent green and red filters. 
Scoring was determined by green and red signals emitted per each nucleus. Each slide 
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required ten nuclei in signal number agreement in multiple locations on each slide for 
ploidy determination. Two signals per nuclei were labeled euploid while three signals 
per nuclei were indicative of the Ts65Dn marker chromosome (Figure 2.1). 
 After the development of a PCR technique for the extrachromosomal segment 
breakpoint found in Ts65Dn mice, PCR was used as described in Reinholdt et al., 2011 to 
genotype all mice in the colony as well as embryos through yolk sac isolation. Yolk sacs 
taken from embryos during dissection were placed in yolk sac lysis buffer with 
Proteinase K (12.5 µl of Proteinase K per 1 ml of yolk sac lysis buffer, 50 µL per yolk sac) 
(Bioline, Taunton, MA) overnight at 55° C, then isolated the next day. To each tube, 0.25 
volume of 5M NaCl was added, then tubes were vortexed and spun for 5 minutes at 
13,000 rpm at 4° C. Supernatant from each tube was transferred to a new tube with 0.8 
volume of isoproponol, vortexed, and left at room temperature for 5 minutes. Tubes 
were spun for 15 minutes at 13,000 rpm at 4° C, and then the supernatant was 
discarded. Pellets were then washed with 50 µl cold 70% ethanol, vortexed, and spun 
for 1 minute at 13,000 rpm at 4° C. Supernatant was discarded and tubes were inverted 
for no more than 5 minutes in order to dry the pellet. Pellets were resuspended in 20 µl 
of sterile distilled millipore water and were kept at 4° C. 
Ts65Dn mice and embryos were genotyped using FISH until the development of 
primers for the breakpoint of the Ts65Dn extrachromosomal segment allowed for 
genotyping of mice and embryos using PCR. This method places primers on either side 
of the breakpoint between Mmu 16 genes and the Mmu 17 centromere of the 
translocation chromosome (REINHOLDT et al. 2011). Primer sequences for the breakpoint 
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were Chr17fwd_5’-GTGGCAAGAGACTCAAATTCAAC-3’ and Chr16rev_5’-
TGGCTTATTATTATCAGGGCATTT-3’ and amplified an approximate 275-bp region. 
Positive control primers utilized were IMR1781_5’-TGTCTGAAGGGCAATGACTG-3’ and 
IMR1782_5’-GCTGATCCGTGGCATCTATT-3’ to amplify a 544-bp product (REINHOLDT et al. 
2011). In at 25 µl reaction mixture, all primers were utilized at a 0.4 µM concentration 
each with 1 µl of DNA from mice and 2 µl of DNA from embryo yolk sacs. PCR cycling 
conditions were 94° C for 2 min, 34 cycles of 94° C for 45 sec, 55° C for 45 sec, and 72° C 
for 1 min, 72° C for 7 min, and a 4° C hold (REINHOLDT et al. 2011). PCR product was 
visualized on a 1.5% agarose gel made with 5 µl of SYBR Safe DNA gel stain (Invitrogen, 
Carlsbad, CA). Ts1Rhr mice and embryos were genotyped as previously established 
(DEITZ and ROPER 2011) using the same isolation techniques as Ts65Dn samples.  
 
2.3 RNA Isolation 
The PA1 and NT of embryos determined to be at the E9.5 developmental stage 
were dissected from the embryos in an RNase free environment using 30 gauge needles. 
Structures dissected were specified by a cut matching the line of the body for the PA1 
and above the otic vesicle but below the midbrain for the NT (Figure 1.7). Tissues were 
placed in RNase free tubes and RNA was extracted using the PureLink RNA Micro Kit 
(Invitrogen, Carlsbad, CA). A final volume of 15 ml of RNA was obtained for each sample 
and quantification of purity and concentration was performed using the Nanodrop ND-
1000 (Thermo Scientific, Waltham, MA) for nucleic acid.  
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2.4 Cell Culture 
For the quantification of cell proliferation and migration, the PA1 and NT were 
removed as described in section 2.3 and placed into 0.025% trypsin/ 0.1% 
collagenase/DPBS (0.01 g collagenase, 100 µl 2.5% trypsin and DPBS to make a 10 ml 
solution) for 4 minutes at 37° C. Cells were triturated approximately ten times per 
sample after incubation and then spun down at 10,000 rpm for 6 minutes. The 
supernatant was extracted from each tube and cells were resuspended in 50 µl of 
MCDM, made of 50 µM 2-mercaptoethanol (1:100 in H2O, Sigma, St. Louis, MO), 35 
ng/ml retinoic acid (1:1000 in DMSO, Sigma, St. Louis, MO), 10% chick embryo extract 
(CEE, Seralab, West Sussex, UK), 20 ng/ml bFGF (Sigma, St. Louis, MO), 1% N2 
Supplement (Invitrogen, Carlsbad, CA), 2% B27 (Invitrogen, Carlsbad, CA), 25 µl 
penicillin/streptomycin (P/S, Invitrogen, Carlsbad, CA) and 8.7 ml of low glucose DMEM 
(Invitrogen, Carlsbad, CA) per 10 ml batch of media, then filtered through a 22 µm filter 
with a 20 ml syringe (ZHAO et al. 2006). Resuspended cells were plated on fibronectin-
coated 96-well plates (Becton, Dickinson and Company, Franklin Lakes, NJ) (proliferation 
assays) or fibronectin-coated coverslips (migration assays). Fibronectin-coated 
coverslips were made on the day of cell seeding. A barrier was created around the 
perimeter of the 22 x 22 mm glass coverslips using a Pap Pen (hydrophobic slide marker, 
Research Products International, Mount Prospect, IL) and allowed to dry for 15 min in at 
60 x 15 mm petri dish. Poly-D-lysine (Sigma, St. Louis, MO) was diluted to 100 µg/ml in 1 
M HEPES Solution (Cellgro, Manassas, VA) and 200 µl of this solution was pipetted onto 
each coverslip. Coverslips were incubated for 30 minutes at 5% CO2 and 37° C. Poly-D-
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lysine was removed from the coverslips and discarded and coverslips were washed 
twice with sterile filtered HEPES. Fibronectin (diluted 1:10 in HEPES, Becton, Dickinson 
and Company, Franklin Lakes, NJ) was added to each coverslip to cover the area inside 
the hydrophobic barrier and coverslips were incubated for 30 minutes at 5% CO2 and 37° 
C in the NAPCO Series 8000 DH CO2 Incubator (Thermo Scientific, Waltham, MA). 
Fibronectin was then removed and discarded and coverslips were again rinsed with 
HEPES. Each coverslip was washed with MCDM before cell seeding. Cells were incubated 
at 5% CO2 and 37° C in MCDM until confluence (approximately 12-24 hours, depending 
on genotype and tissue). During migration assays, media changes occurred daily until 
assays were completed. 
 
2.4.1 Proliferation Assay 
Cells derived from PA1 and NT tissues were dissected from the embryo as shown 
in Figure 3.1A and were treated with trypsin/collagenase/DPBS to ensure breakdown of 
the tissues into individual cells. Cells were grown on the 48 well plate for 24 hours, then 
were quantified for cell titer using a hemacytometer. For proliferation assays, cells were 
grown to confluency on 96 well plates, transferred to 48 well plates, quantified, and 
replated on new wells at a density of approximately 1 x 104. From each sample 
consisting of suspended cells and 200 µl MCDM, 10 µl was removed for quantification. 
For each cell titer, three counts were taken on a hemocytometer and average to obtain 
a cell titer per 4 x 10-3 mm2, representative of 1/25 of the original sample. To obtain the 
number of cells per cubic millimeter (or one microliter), this value was multiplied by 25. 
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Lastly, to obtain the titer for the remaining sample in the well, the value was multiplied 
by the remaining volume or 190 µl. Therefore, cell titer was established by 4750 x the 
average number of cells counted (FREI 2011). Cell titer was adjusted to 1x104 for all wells 
to account for alterations in PA1 size and growth parameters before treatment.  
Cells were allowed to grow on the plate for eight hours, media was replaced and 
the AQueous One Cell Titer Solution (Promega, Madison, WI) was added to each well for 
four hours, including one control well containing no cells. Cells were treated with 
dimethyl sulfoxide (DMSO, Fair Lawn, NJ), (-) Epigallocatechin gallate (EGCG) from green 
tea (Sigma, St. Louis, MO) in DMSO or harmine (Sigma, St. Louis, MO) in DMSO. EGCG 
treatments included doses of 10 µM, 25 µM and 100 µM in DMSO and harmine 
treatments included doses of 1 µM and 10 µM in DMSO for four hours, then the media 
was replaced and cells were incubated with MCDM only for four hours. Cell Titer 96 
AQueous One Solution Reagent was added to each well and one control well with media 
and incubated for four hours. This solution contains an MTS tetrazolium compound 
which is bioreduced by proliferating cells through dehydrogenase enzymes into a 
colored formazan product which is soluble in MCDM. For quantification, 100 µl of 
supernatant was collected from each cell sample. Proliferation was assessed using a 
spectrophotometer at 490 nm and plotted on a standard curve to determine the 
number of cells in each well. Proliferation of trisomic and euploid tissues was compared 
within the cell assay to determine fold changes of proliferation for each trisomic sample 
relative to euploid samples.  
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2.4.2 Migration Assay 
Cells were placed on fibronectin-coated coverslips to allow for ease of access to 
the cell and growth substrate. Plated cells were incubated at 5% CO2 and 37° C for 24 
hours in MCDM or until confluent, and then the scratch assay was performed as 
described (LIANG et al. 2007) by creating a diagonal scratch across the cell layer on the 
coverslip (Figure 2.2). Media was changed to remove and debris from the scratch and 
cells were treated for four hours with DMSO, EGCG in DMSO or harmine in DMSO at 
concentrations described in section 2.4.1. Pictures were taken at 0, 24, 48, and 72 hours 
after the scratch was made for quantification of migration. MCDM was changed daily 
with care taken to avoid disturbing the cells. Using Image J, the number of cells in the 
scratch were quantified and recorded as follows: each scratch was outlined to ensure 
conformity among scratch width before proceeding to quantification. Any images with 
inconsistent scratch widths were not utilized in this analysis. Using the counting tool, 
the number of cells within each scratch not touching the borders outlining the scratch 
was quantified for three images per culture. An average of these three numbers was 
then used as a migration count for that sample. Migration rates were established as the 
number of cells fully migrated into the scratch divided by the length of time since the 
scratch test was initiated in hours. Trisomic migration rates were then compared to 
euploid migration rates of the same tissue and culture group. 
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2.5 Quantitative (q)PCR 
RNA was thawed from storage at -80˚ C for conversion to cDNA. Using the 
TaqMan Reverse Transcription Reagents (Applied Biosystems, Carlsbad, CA) a master 
mix was created for conversion to cDNA. For each reaction, 29.5 µl master mix, 19.25 µl 
of RNA (samples were diluted using sterile millipore water), and 1.25 µl reverse 
transcriptase were used to convert one sample of RNA to cDNA. Using this cDNA, master 
mixes were created for the reference gene (actin, Ev1) and 3 target genes. Each master 
mix consisted of 4 µl PCR grade water, 1 µl of probe, and 10 µl of TaqMan Gene 
Expression Master Mix (Applied Biosystems, Carlsbad, CA) for a total of 15 µl of master 
mix per well. For this analysis, 12 wells were utilized per probe and genotype, with 
trisomic and euploid genotypes requiring a total of 24 wells per probe. Therefore, the 
reaction described was multiplied by 24 to fill a plate appropriately with probe master 
mix. To the corresponding wells, as shown in Figure 2.3, 5 µl of cDNA was added with 
care taken not to contaminate cDNA samples or probe master mix already in the plate. 
Samples were then analyzed in duplicates using the AB 7300 Real Time PCR System 
(Applied Biosystems, Carlsbad, CA). Each plate was run with reference gene and 3 target 
genes (12 cDNA samples or 6 Eu and 6 Ts samples per plate) (Figure 2.3). Crossing point 
(Cp) values from each duplicate trisomic sample were then averaged and divided by the 
average Cp value of the two euploid samples as performed by the 7300 System Software 
(Applied Biosystems, Carlsbad, CA). Relative quantification was performed on Ts65Dn 
and euploid littermate PA1 from both treated and untreated embryos. Expression was 
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quantified for Ev1 (actin, housekeeping gene), Dyrk1a, Rcan1, Shh, Gli1, Ptch1, and Ets2 
probes. Expected euploid levels of expression are equal to 1 for comparisons. 
 
2.6 In vivo Assessment of the Effects of EGCG 
 
2.6.1 Treatment Technique 
In order to study the effects of EGCG in vivo, Ts65Dn females bred with Wnt1-
lacZ males were utilized. Pregnancy was established by the presence of a vaginal plug on 
the morning after breeding. Pregnant females were weighed on the day of plug and 
daily on E7-E9. Females which gained approximately two grams by E7 since the day of 
establishment of the plug were orally gavaged using a 22 gauge needle with PBS or 
EGCG in diluted in PBS. Mice were treated with 200 mg/kg body weight using 20 mg/ml 
or 150 mg/kg body weight using 15 mg/ml (5 Eu mothers, 5 Ts mothers) solution or PBS 
(1 Eu mother, 2 Ts mothers) of equivalent volume twice daily on E7 and E8 with 
approximately 8 hours between doses. Mice were strictly monitored for general health 
assessed by daily weight changes, locomotor activity in the cage, and response to 
handling over the two day period of treatment before euthanizing.  
 
2.6.2 Embryo Processing 
Females were euthanized at E9.5 and whole embryos were dissected. Yolk sacs 
were obtained for genotyping by PCR and embryos were fixed 0.2% gluteraldehyde with 
5 mM EGTA and 2 mM MgCl2 in 0.1 phosphate buffer for 15 min at room temperature, 
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washed three times for 5 min each in was buffer (2 mM MgCl2, 0.02% Nonidet P-40 in 
0.1 M phosphate buffer) and stained with 0.025% 5-bromo-4-chloro-3-indoyl-β-D-
galactopyranoside in 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide for 1 
h at 37° C. Embryos were then washed in wash buffer and postfixed in 4% 
paraformaldehyde overnight at 4° C. The following day, embryos were processed 
through dehydration in 1 ml increasing concentrations of ethanol (10 min each in 50%, 
70%, 70%, 95%, 95%, 100%, and 100% ethanol), clearing with xylenes (10 min in 1:1 100% 
ethanol:Xylenes, 10 min Xylenes, and 10 min Xylenes), and infiltration with paraplast at 
58° C (20 min in 1:1 Xylenes:paraplast, 20 min paraplast, and 20 min paraplast). Embryos 
were embedded parasagittally in paraffin wax, and then moved to a cold block for the 
paraplast to solidify. Embryos were cured at 4°C for seven days before sectioning. 
 
2.6.3 Histology 
Whole, cured, embedded embryos were exhaustively sectioned parasagittally 
using a standard microtome set to 18µm thickness per section with 5 sections per single 
slide. Sections were kept on a slide warmer at approximately 37° C overnight, and then 
were melted for one hour at 55° C the next day to ensure that sections adhered to the 
glass slide. Sections were further processed by CitriSolv (Fisher Scientific, Kalamazoo, MI) 
washes (4 min, repeated three times or until all wax was removed) to remove excess 
paraplast, ethanol clearing (2 min in 100% ethanol, repeated once, 1 min in 95% ethanol, 
and 1 min in 70% ethanol), counterstaining with 0.1% Eosin (Fisher Scientific, Kalamazoo, 
MI) in 100% ethanol (3-4 dips in solution, then 2 min), ethanol for clearing and excess 
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stain removal (10 sec in 95% ethanol, 15 sec in 95% ethanol, 1 min in 100% ethanol, 
repeated once), and CitriSolv washes for final processing (3 min, repeated three times). 
Slides were then coverslipped with 24 X 60 mm glass coverslips and DPX mountant 
(VWR, West Chester, PA) and were allowed to cure one week at room temperature. 
 
2.6.4 Stereological Analysis 
 Fully processed embryos were assessed for proper orientation and visibility of 
the PA1 using a dissecting microscope and were then subjected to unbiased stereology. 
Sections were sampled as follows: the PA1 was assessed sampling every third section 
containing PA1 starting with a randomly generated number between one and three; 
embryonic volume and assessed sampling every fourth section starting with a randomly 
generated number between one and four. Parameters for the study were as follows 
established through the principles outlined in Mouton, 2002: for PA1 volume 
measurement, every third section with arch tissue was analyzed by stereology starting 
at a random start point chosen by a random number generator. Cells in the PA1 were 
counted using dissectors spaced at intervals of 60 µm with dimensions of 150 µm2 area 
and 8 µm depth with a 2 µm guard height. Average CE for all volumes and cell counts 
was ≤ 0.10. Statistical differences were determined using a one-tailed Student’s t-test. 
Systematic random sampling was used to quantify the number of cells in the PA1 and 
Calvalieri-point counting was utilized from volumetric measurements (MOUTON 2002). 
Region point counting was utilized to quantify embryo volume. Embryo volume was 
assessed with the following parameters: a frame area of 25 µm2, 10 µm frame height, 2 
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µm guard height, 200 µm from spacing, 8000 µm2 area per point, and sampling from the 
top of the section. Average CE values for embryo volumes were ≤ 0.01. Statistical 
differences were determined using a one-tailed Student’s t-test.  
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CHAPTER 3. RESULTS: GENETIC DYSREGULATION AND MODIFICATION IN VITRO 
3.1 Dyrk1a and Rcan1 Are Dysregulated in the Ts65Dn E9.25 and E9.5 PA1 and NT 
 Dysregulation of Dyrk1a and Rcan1, independently and in concert, are 
hypothesized to influence craniofacial phenotypes via dysregulation of the transcription 
factor, NFATc, in its localization in the cell (ARRON et al. 2006). In order to determine the 
extent of their dysregulation on the craniofacial phenotypes observed in Ts65Dn, PA1 
and NT tissues (Figure 3.1A) from E9.25 and E9.5 embryos were collected and RNA was 
extracted for analysis through qPCR. Samples run in duplicate showed downregulation 
of Dyrk1a and upregulation of Rcan1 in the E9.25 PA1 and NT (Figure 3.1B). Interestingly, 
Dyrk1a relative expression (relative Ts65Dn expression to euploid expression) was 
upregulated and Rcan1 was downregulated in the E9.5 PA1 and NT (Figure 3.1C). 
Furthermore, at E13.5 relative expression levels of Dyrk1a and Rcan1 are upregulated in 
the PA1 (Figure 3.1D). The fluctuations in gene expression of these two genes relative to 
one another suggest an inverse relationship of regulation (Figure 3.2). Due to the 
relationship between Dyrk1a and Rcan1 regulation and their hypothesized role in the 
developing embryonic mandible, the role of Dyrk1a in many DS phenotypes including 
cognition and brain development, and the availability of Dyrk1a modifiers, we 
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hypothesized that altering the activity of Dyrk1a could ameliorate the known cellular 
deficit in the PA1 at E9.5. 
 
3.2 Dyrk1a and Rcan1 Are Dysregulated in the Ts1Rhr E9.5 PA1 
Ts1Rhr mice display a large, dysmorphic mandible as adults (OLSON et al. 2004a) 
and these alterations can be traced back to the developing PA1 at E9.5 (DEITZ and ROPER 
2011). In order to determine what molecular changes occurred in the PA1 to cause 
these alterations at E9.5, the expression of Dyrk1a, Rcan1, and the transcription factor 
Ets2 were studied for at E9.5 in the PA1 of Ts1Rhr embryos (Figure 3.3). Though strain-
specific differences were present, Dyrk1a was upregulated in the PA1 and Ets2 was 
downregulated in the PA1 (DEITZ and ROPER 2011). Dependent on strain, Rcan1 was 
either up- or downregulated, however (DEITZ and ROPER 2011). The changes in regulation 
of these genes compared to that of the same structure and time point in Ts65Dn 
presents an interesting paradigm to study craniofacial alterations stemming from 
cellular alterations in proliferation and migration in the PA1 and NT tissues. 
 
3.3 Ts65Dn Embryo PA1 and NT Display Proliferation and Migration Deficits In Vitro 
 Ts65Dn embryos at E9.5 display a smaller PA1 with fewer NCC than their somite-
matched euploid littermates and fewer NCCs appear to migrate from the NT to the PA1 
prior to this time point (ROPER et al. 2009). We cultured E9.5 PA1 and NT cells and 
assessed their propensity for proliferation and migration in vitro to confirm the 
reproducibility of previously published results and improve assay conditions (ROPER et al. 
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2009). Using a colorimetric assay of confluent, untreated trisomic and euploid E9.5 PA1 
and NT cells to quantify proliferation revealed a proliferation deficit in trisomic PA1 and 
a similar proliferation level in trisomic NT when compared to euploid cells of the 
corresponding tissues (Figure 3.4). Previous methodologies utilized to measure 
proliferation and originally classify the proliferation deficit included the use of 
previously embedded E9.5 embryos which were stained with cresyl violet to mark 
mitotic and apoptotic cells (ROPER et al. 2009). Results previously published described a 
reduction in NCC in the PA1 of Ts65Dn E9.5 embryos compared to euploid littermates. In 
addition, these investigators also examined proliferation at E9.25 by culturing cell 
suspensions derived from a single PA1 each, and found fewer cells in wells containing 
cells from trisomic PA1 tissue compared to cells from euploid PA1 tissue. 
 To assess the migratory abilities of cells in the E9.5 PA1 and NT, cells were 
isolated as described and subjected to a migration assay using fibronectin-coated 
coverslips. Images taken at 24, 48, and 72 hours revealed that trisomic cells took longer 
to reach a state of confluency compared to euploid cells. Figure 3.5, panel 1 shows 
images taken at identical time points post plating, which illustrates the initial cellular 
deficit and growth delay indicated by slower overall migration of the confluent layer of 
cells into the scratch.  
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3.4 Ts1Rhr Embryos Do Not Display Proliferation or Migration Deficits In Vitro 
 Ts1Rhr cell culture assays were employed to better understand the molecular 
mechanism of action for EGCG. Ts1Rhr E9.5 PA1 and NT cells were subjected to 
proliferation and migration assays independently. Ts1Rhr cells proliferated similarly to 
euploid cells in both the PA1 and NT and appeared to display no significant alterations in 
proliferation rate. Cells from the E9.5 PA1 and NT of Ts1Rhr embryos were also cultured 
for migratory potential as previously described. Ts1Rhr cells displayed no initial 
migration deficit when compared to euploid cells over a culture period of 72 hours 
(Figure 3.6).  
 
3.5 EGCG Ameliorates Ts65Dn Embryo Proliferation and Migration Deficits In Vitro 
Untreated trisomic and trisomic treated with EGCG proliferation rates were 
compared to euploid rates in order to derive a fold change in proliferation between the 
cell populations. Trisomic cells derived from the Ts65Dn PA1 treated with DMSO 
proliferated significantly less than euploid cells in both the PA1 and NT at E9.5. 
Treatment of PA1 cells with 10 µM EGCG led to a significant increase in proliferation of 
cells in the PA1, but also a significant decrease in the proliferation of cells from the NT. 
Changes in trisomic PA1 proliferation were not sufficient to reach euploid levels at this 
concentration of EGCG, however. Treatment with 25 µM EGCG was sufficient to 
ameliorate the trisomic PA1 proliferation deficit without altering NT proliferation 
significantly. Lastly, treatment with 100 µM EGCG led to an overabundance of 
proliferation in both PA1 and NT cells to significant levels above euploid proliferation 
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(Figure 3.7). Interestingly, no initial proliferation deficit was seen in trisomic cells 
derived from the NT of E9.5 Ts65Dn embryos and this was maintained at the 25 µM 
EGCG dosage. A dose-dependent response to EGCG was thus observed in cells derived 
from the PA1, showing an optimal treatment dosage, but also indicating excessive EGCG 
on proliferation rates in vitro. Treatment of cells derived from the NT with EGCG showed 
a similar response in trend to that of treated cells from the PA1 (Figure 3.7).  
 Migration assessment of Ts65Dn and euploid PA1 and NT cells was performed 
using the scratch assay followed by treatment with DMSO or EGCG treatment for four 
hours. Ts65Dn PA1 cells treated with 10 µM EGCG showed a significant increase in 
migration compared to DMSO treatment, leading to euploid levels of migration over the 
72 hours of the assay. This concentration of EGCG treatment led to an increase in 
migration of Ts65Dn NT cells, also, which reached near euploid levels after 72 hours in 
culture (still a significant increase over trisomic cell migration with DMSO treatment). 
Optimal migration was observed with 25 µM EGCG treatment of PA1 and NT cells when 
compared with migration rates of cells from euploid samples (Figure 3.8A and 3.8B). As 
with EGCG treatment in proliferation, a dose-dependent response was observed in 
migration rates for EGCG treated trisomic cells.  
 
3.6 EGCG Does Not Alter Ts1Rhr Embryo Proliferation or Migration In Vitro 
Proliferation of Ts1Rhr cells isolated from the PA1 and NT were also assessed 
using treatment with DMSO, 10 µM EGCG, or 25 µM EGCG. Analysis of cells treated with 
DMSO revealed significantly higher levels of proliferation in Ts1Rhr E9.5 PA1 cells 
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compared to euploid cells, but a proliferation deficit was observed in DMSO treated 
trisomic NT cells compared to euploid cells. Upon addition of 10 µM EGCG, Ts1Rhr cells 
from the PA1 and NT proliferated similarly to euploid cells but these proliferation rates 
were not significantly different from untreated trisomic cell proliferation rates. 
Treatment of Ts1Rhr PA1 and NT cells with 25 µM EGCG led to euploid levels of 
proliferation in both tissue types, established by a significant decrease in PA1 
proliferation and a significant increase in NT proliferation. Treatment of E9.5 Ts1Rhr PA1 
and NT cells with 100 µM led to a slight increase in PA1 cell proliferation (not 
significantly different from DMSO treated cells) and an increase in NT cell proliferation 
(not significant). Thus, no dose-dependent trends are observed in E9.5 Ts1Rhr PA1 and 
NT cells as were seen in cells derived from the E9.5 Ts65Dn PA1 and NT (Figure 3.9).  
Ts1Rhr cells from the PA1 and NT treated with DMSO showed slight but not 
significant decreases in migration after initiation of the scratch assay; however, this 
alteration was ameliorated by the end of the 72 hour assay. Treatment of trisomic PA1 
and NT cells with 10 µM EGCG led to a significant increase in PA1 cells to above euploid 
levels and a significant increase of NT cells to euploid levels with a slight decrease 
occurring over the 72 hour assay. Significant increases of migration to euploid levels also 
occurred in both PA1 and NT cells from Ts1Rhr E9.5 embryos. EGCG treatment appeared 
to alter migration only slightly over time, but values did not reach significance when 
compared to baseline migration in most treatment conditions (Figure 3.10). 
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3.7 Harmine Ameliorates Ts65Dn Embryo Proliferation Deficits In Vitro 
Harmine, a small molecule inhibitor of Dyrk1a which binds the ATP binding 
pocket of the protein (ADAYEV et al. 2011), was also assessed for the same parameters of 
EGCG in cells from E9.5 Ts65Dn PA1 and NT. After establishing the deficits previously 
described in Ts65Dn cell culture with DMSO treatment, Ts65Dn PA1 and NT were 
cultured with 1 µM harmine, resulting in a significant increase in proliferation of PA1 
cells to euploid levels and a slight increase in NT proliferation. Interestingly, euploid cells 
treated with 1 µM harmine displayed an increase in PA1 and NT proliferation to above 
euploid levels and those in trisomic cells treated with the same concentration of 
harmine. Treatment of Ts65Dn PA1 and NT cells with 10 µM harmine led to euploid like 
proliferation in trisomic PA1 and NT cells and an increased level of proliferation of 
euploid PA1 and NT cells above normal levels. Figure 3.11 shows a dose-dependent 
response of PA1 and NT cells to increasing concentrations of harmine, with optimal 
proliferation occurring at 1µM. Included in these figures and worthy of mention is the 
increase in proliferation observed in euploid samples in the presence of harmine.  
 
 
3.8 Harmine Does Not Alter Ts1Rhr E9.5 Embryo PA1 Proliferation In Vitro 
 Assessment of proliferation in E9.5 Ts1Rhr PA1 and NT with DMSO or harmine 
treatment showed similar trends to EGCG in the NT. Treatment of E9.5 Ts1Rhr PA1 and 
NT cells with 1 µM harmine led to no change in proliferation in the PA1, while trisomic 
NT proliferation was rescued to euploid levels shown by a significant difference from 
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initially deficient proliferation of DMSO treated cells. Euploid cells treated with harmine 
showed a vigorous increase in proliferation compared with trisomic cells from the PA1 
and NT and euploid cells from the PA1. 
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CHAPTER 4. RESULTS: THE EFFECTS OF EGCG IN VIVO 
4.1 In Vivo EGCG Treatment Does Not Affect Litter Size 
Litter sizes produced by E9.5 from pregnant females receiving EGCG or the 
equivalent volume of PBS on P7 and P8 of embryonic gestation were analyzed among 
four treatment groups using a preliminary cohort of animals: Ts65Dn mothers receiving 
EGCG, Ts65Dn mothers receiving PBS, euploid mothers receiving EGCG, and euploid 
mothers receiving PBS. Litter sizes were variable both among treatment groups and 
within the groups themselves. Overall, treatment did not adversely impact litter size, as 
euploid mothers receiving EGCG and Ts65Dn mothers receiving EGCG produced 
equivalent or larger litter sizes, respectively, than Ts65Dn mothers receiving PBS and as 
previously published (ROPER et al. 2006b), and produced similar litter sizes to euploid 
mothers receiving PBS (Figure 4.1).  
 
4.2 In Vivo EGCG Treatment Does Alter Embryonic Developmental Stage at E9.5 
Embryos from Ts65Dn and euploid pregnant females receiving EGCG and PBS 
were analyzed for developmental stage by somite number. Average somite numbers 
from each treatment group were quantified and no differences were found in average 
somites between embryo genotypes and treatment (Figure 4.2). Furthermore, a 
distribution of somite number for each litter from each treatment group indicated no 
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apparent alterations in average somite number, but an increased range of somites 
occurring in litters from mothers receiving EGCG (Figure 4.3). 
 
4.3 EGCG Increases PA1 Cell Number in Trisomic and Euploid Embryos In Vivo 
Embryos derived from pregnant females receiving EGCG and PBS were subjected 
to quantification using unbiased stereology of sections from whole mount embryos. 
Analysis of the number of cells in the PA1 of trisomic and euploid embryos from the two 
treatments revealed a cellular deficit in the trisomic PA1 compared to euploid, somite-
matched littermates receiving PBS, as previously established (Figure 4.4) (ROPER et al. 
2009). Trisomic embryos receiving EGCG showed an increase in cell number in the PA1 
to euploid levels. In addition, euploid embryos receiving EGCG also displayed an 
increase in cell number in the PA1 above that of euploid embryos receiving PBS. 
 
4.4 EGCG Increases PA1 and Embryo Volume In Vivo 
Embryos receiving EGCG and PBS treatment were also assessed for PA1 and 
embryonic volume. Analysis of PA1 volumes revealed a smaller PA1 in trisomic embryos 
receiving PBS compared to euploid embryos receiving PBS, as previously established 
(ROPER et al. 2009). When receiving EGCG, trisomic PA1 volumes increased significantly 
compared to trisomic embryos receiving PBS, but not to the level of euploid PA1 
receiving PBS. Furthermore, euploid embryos receiving EGCG showed a significant 
increase in PA1 volume compared to euploid embryos receiving PBS (Figure 4.5). 
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 Analysis of embryonic volume of treatment groups reveled similar relationships. 
Trisomic embryos receiving PBS were significantly smaller than euploid embryos 
receiving PBS, and the addition of EGCG was not sufficient to change this relationship. 
However, euploid embryos receiving EGCG displayed an increased embryo volume 
significantly different from that of euploid embryos receiving PBS (Figure 4.6). 
 
4.5 EGCG Alters Expression of Genes in Pathways Implicated in Craniofacial 
Development In Vivo 
Embryos obtained from mothers receiving EGCG or equivalent volume PBS on E7 
and E8 were utilized for gene expression analysis. Using qPCR to analyze relative 
expression of Dyrk1, Rcan1, Shh, Gli1, Ptch1, and Ets2, all of which are implicated in 
craniofacial or developmental pathways (ARRON et al. 2006; HILL et al. 2009; HU and 
HELMS 1999), in the PA1 of embryos receiving EGCG or PBS, we found that EGCG 
exposure leads to altered relative expression of several of these genes in the PA1. 
Baseline expression of these genes (relative expression of Ts PA1/Eu PA1) was as follows: 
1.54 fold Dyrk1, 0.57 fold Rcan1, 0.55 fold Shh, 1.32 fold Gli1, 1.16 fold Ptch1, and 1.41 
fold Ets2 expression (Figure 4.7). Treatment of Ts65Dn embryos with EGCG revealed 
significant decreases in Ptch and Ets2 expression in the PA1 and significant increases in 
Rcan1 and Shh expression relative to original baseline expression values in the PA1 were 
observed (Figure 4.7). Other permutations of relative expression were also analyzed to 
better understand the effects of EGCG on the expression of these genes (Figure 4.7). 
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CHAPTER 5. DISCUSSION 
5.1 Dysregulation of Dyrk1a and Rcan1 at E9.5 May Lead to Altered NFAT Activity 
and Bone Development 
Craniofacial alterations are present in all individuals with DS and interfere with 
daily functions of these individuals when combined with other DS phenotypes (such as 
hypotonia), leading to secondary health issues, such as failure to thrive and sleep apnea. 
These secondary phenotypes can lead to additional health concerns in a perpetuating 
cycle, such as long-term cognitive deficits (HALBOWER et al. 2006) and poor school 
performance (GOZAL 1998). Using the Ts65Dn mouse model, an origin of the cell deficit 
which leads to a deficient mandible in individuals with DS and this mouse model was 
traced to midgestation of mouse development, E9.5. From this information, we 
confirmed both a cellular deficit in proliferation and migration at this time point as 
described in Ts65Dn embryos (ROPER et al. 2009). Analysis of the PA1 which contributes 
to the mandible, as well at the NT from which neural crest cells which populate the PA1 
are derived, using qPCR revealed genetic dysregulation of two genes known to regulate 
the transcription factor Nfatc, Dyrk1a and Rcan1. At E9.25, Ts65Dn display a 
downregulation of Dyrk1a and upregulation of Rcan1 in the PA1, but an inverse in 
expression levels in the PA1 at E9.5. The continued changes in the cycling of Dyrk1a and 
Rcan1 throughout various stages of development in the Ts65Dn PA1 also appear to 
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correlate with changes in the PA1 size relative to euploid littermates. At E9.25, no 
changes appear in the PA1 relative to euploid, stage-matched littermates and Dyrk1a is 
slightly downregulated, while Rcan1 is upregulated. At E9.5, Ts65Dn embryos display a 
smaller PA1 than euploid littermates, but display upregulation of Dyrk1a and 
downregulation of Rcan1. At E13.5, Dyrk1a is highly downregulated, while Rcan1 is 
highly upregulated in the PA1 where a smaller mandibular precursor is present with 
regard to the embryonic size. Interestingly, the tongue is of similar size in trisomic and 
euploid embryos, leading to a relative macroglossia in trisomic embryos. Information 
provided here indicates that dysregulation of these genes appears to initiate changes in 
the PA1 with genetic dysregulation traced back to E9.25, leading to the changes 
observed at E9.5 through E13.5 in development. This data may indicate the key roles for 
Dyrk1a and Rcan1 regulation of NFAT in the proliferation and migration of NCC from the 
NT to the PA1 in this critical time window around E9.5. 
Regulation of NFAT localization is particularly important in the PA1 (which 
contributes to the mandible and other facial bones) due to its ties to bone development. 
Members of the NFAT family of transcription factors are known to control bone 
homeostasis, including bone resorption and formation by osteoclasts and osteoblasts, 
respectively (SITARA and ALIPRANTIS 2010). Furthermore, Dyrk1a has been shown to inhibit 
Nfatc1 and transgenic mice overexpressing Dyrk1a have been shown to display 
significantly reduced bone mass reminiscent of the osteoporotic bone phenotype seen 
in individuals with DS (LEE et al. 2009). In addition, harmine, the Dyrk1a inhibitor also 
used in the cell culture experiments described here, has been shown to lead to 
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dephosphorylation of Nfatc1, disruption of events mediating osteoclastogenesis, and 
repression of bone resorption (EGUSA et al. 2011; YONEZAWA et al. 2011). Considering the 
evidence presented here, it is likely that dysregulation of NFAT localization due to 
dysregulation of Dyrk1a, Rcan1, or both, may lead to alterations in bone phenotypes not 
only in the developing craniofacial skeleton, but throughout the body. 
 
5.2 Gene Dysregulation is Temporally Altered through Midgestation in the PA1 
The condition of Down syndrome (DS), or Trisomy 21, leads to the dosage 
imbalance of genes on Hsa 21, and theoretically should lead to an approximately 1.5 
fold relative expression of trisomic genes compared to euploid genes or the same genes 
from normosomic samples. However, several investigators have published evidence 
suggesting that genomic imbalance does not necessarily translate to transcript level, 
and thus other mechanisms regulate this process (KAHLEM et al. 2004; LYLE et al. 2004). In 
order to quantify regulation of trisomic genes Dyrk1a and Rcan1 at the early stages of 
PA1 development, we performed qPCR on the PA1 or mandibular precursor of E9.25, 
E9.5, E10, and E13.5 embryos. Expression level of the two genes oscillated over the 
course of these time points with values upregulated for one gene and downregulated 
for the other at every time point except E13.5, when both genes are upregulated in the 
PA1. This regulation is reminiscent of the patterns of a feedback loop and may be 
indicative of a mechanism of regulation between the two genes. A recent study 
published the direct interaction of Dykr1a and Rcan1 via the phosphorylation of Rcan1 
at Ser(112) and Thr(192) by Dyrk1a, increasing the ability of Rcan1 to inhibit the 
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phosphatase activity of calcineurin, causing reduced Nfat activity (JUNG et al. 2011). In 
addition, a brief inquiry into the regulation of these two genes when one is altered in 
copy number was undertaken by our laboratory. PA1 and NT tissue from Dyrk1a 
heterozygous embryos (mice with a normal genetic complement but just a single copy 
of Dykr1a) was used for qPCR analysis to better understand the effects of altering the 
copy number of one gene in this system on the other. This brief study revealed an 
upregulation of Rcan1 in the presence of fixed downregulated Dyrk1a in the PA1 and NT. 
It is important to note, however, that Dyrk1a heterozygous mice are bred on an 
alternative background to that of Ts65Dn and Ts1Rhr mice and care should be taken in 
making comparisons in relative expression of genes between models (DEITZ and ROPER 
2011). This data compiled with previously published studies suggests a feedback loop 
which maintains expression levels opposite in directionality of expression (upregulated 
versus downregulated), but in equal magnitude (Figure 5.1). 
 
5.3 EGCG and Harmine Ameliorate Proliferation and Migration Deficits in Ts65Dn 
PA1 and NT Tissues In Vitro 
Ts65Dn embryos at E9.5 display a proliferation and migration deficit in the PA1 
and NT, respectively. Dyrk1a, a gene trisomic in Ts65Dn and in individuals with DS, is 
upregulated in the PA1 of Ts65Dn embryos at E9.5. Since EGCG and harmine are known 
Dyrk1a inhibitors, with much more known about the specific actions of harmine on 
Dyrk1a, we investigated the effects of these inhibitors in vitro on cells derived from the 
Ts65Dn PA1 and NT. Treatment with 25 µMM EGCG was sufficient to ameliorate 
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proliferation and migration deficits in Ts65Dn PA1 and NT cells, respectively, but lower 
levels of EGCG were not sufficient to produce euploid levels of proliferation and 
migration in Ts65Dn cells.  
Treatment of Ts65Dn cells with harmine led to similar results with 1 µM and 10 
µM concentrations, ameliorating proliferation and migration deficits in the PA1 and NT 
of Ts65Dn embryos, respectively. Interestingly, harmine treatment led to excessive 
euploid cell proliferation in both and tissue types.  
 
5.4 EGCG and Harmine Alter Proliferation and Migration in Ts1Rhr PA1 and NT 
Tissues In Vitro 
Ts1Rhr embryos display a mild proliferation deficit in the NT. Dyrk1a is also 
trisomic in Ts1Rhr mice and is upregulated in the PA1 of Ts1Rhr embryos at E9.5. Since 
EGCG and harmine are known Dyrk1a inhibitors, we also investigated the effects of 
these inhibitors in vitro on cells derived from the Ts1Rhr PA1 and NT in order to examine 
the effects of these inhibitors in a system with slight gene copy number differences and 
dramatic craniofacial differences. Treatment of cells with 10 µM, 25 µM, and 100 µM 
EGCG was able to improve NT proliferation to euploid levels in Ts1Rhr and without 
affecting PA1 proliferation. All concentrations of EGCG tested on PA1 and NT cells from 
euploid samples derived from Ts1Rhr litters displayed nominal effects.  
Treatment of Ts1Rhr PA1 and NT cells with 1 µM harmine ameliorated NT 
proliferation deficits in Ts1Rhr embryos, but also led to excessive euploid cell 
proliferation in both tissue types. Though this was not specifically studied in cells 
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treated with EGCG, post hoc testing also showed an increase in EGCG treated euploid 
cells compared to those receiving DMSO. Proliferation increases in both euploid and 
trisomic cells may be indicative of later phenotypic changes occurring as a result of 
treatment with harmine and this change may also be indicative of underlying genetic 
alterations, as was hypothesized. 
Of relevance in the context of these results are the mechanisms known or 
hypothesized for these two compounds. Harmine acts through a specific mechanism in 
which it inhibits Dyrk1a activity by interacting with the residues of the ATP binding 
pocket (BECKER and SIPPL 2011). In addition, it has been shown to have no adverse effects 
on cell viability in culture (GOCKLER et al. 2009). EGCG on the other hand has primarily 
only been studied in cancer systems, and in this case, expression of metastasis-
associated 68-kDa laminin receptor confers EGCG responsiveness. However, one study 
performed using a mouse transgenic for Dyrk1a revealed that mice receiving green tea 
polyphenols displayed a correction of brain morphogenesis alterations and 
improvements in long term memory (GUEDJ et al. 2009). Despite the general lack of 
information regarding the effects of EGCG, we can hypothesize from the results 
provided here that EGCG and harmine act on Dyrk1a similarly, likely leading to a 
reduction in Dyrk1a activity or expression to produce these effects in vitro.  
 
5.5 EGCG Does Not Negatively Impact Embryonic Development In Vivo 
In preparing for an in vivo study, careful consideration was taken to determine 
which Dyrk1a inhibitor, EGCG or harmine, would be most appropriate as a gavage 
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treatment for pregnant Ts65Dn mothers. Despite a well-known mechanism of action for 
harmine on Dyrk1a, it is also known to act as an inhibitor for monoamine oxidase A (KIM 
et al. 1997; RIBA et al. 2003). Monoamine oxidase A functions continuously to catalyze 
the deamination of amines, such as norepinephrine, epinephrine, dopamine, and 
serotonin, in the brain and peripheral tissues by producing hydrogen peroxide as a 
byproduct (SHIH 1991; THORPE et al. 1987). Inhibiting this enzyme through use of harmine 
in an in vivo treatment could cause a toxic buildup of neurotransmitters throughout the 
body. Furthermore, EGCG is known to have the ability to cross the blood-brain and 
placental barriers (CHU et al. 2007) and has been used in previous in vivo studies through 
oral gavage, intraperitoneal injections, and ad libitum feedings (AMIN et al. 2010; GUEDJ 
et al. 2009; LONG et al. 2010). It is also widely available already to the public and, after 
water, tea is the most common beverage consumed in the world, having been a part of 
the Chinese diet for over 5000 years (MAK 2012; SARTIPPOUR et al. 2002). Therefore, due 
to its low toxicity, well-characterized health impacts, and potential for translational uses 
in humans, EGCG was chosen for the in vivo studies investigating the effects of Dyrk1a 
inhibition on NCC population of the PA1 and embryonic size. 
Analysis of litter size produced from Ts65Dn and euploid mothers treated with 
EGCG and PBS revealed no negative impacts of EGCG on litter. In fact, litter sizes showed 
improvement in Ts65Dn females treated with EGCG compared to Ts65Dn females 
treated with PBS. Since EGCG has previously been shown to be effective in oral gavage 
techniques in the aim to have treatment reach developing embryos in pregnant females 
(LONG et al. 2010), there was little concern for toxic effects on the embryos. However, it 
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should be noted that several females were sacrificed on E9.5 that appeared to have 
been pregnant on E7 according to weight gain (2 grams or more), but contained only 
resorbed embryos and a swollen, vascularized uterus (Figure 5.2). We hypothesize that 
the physical stress of the gavage may have deterred pregnant females from consuming a 
regular intake of food and water as well as added an additional stress to their 
environment, causing a loss of pups between E7 and E9.5 of embryonic development.. 
Due to the lack of adverse impact of EGCG on litter size in Ts65Dn females, we have 
hypothesized that the concentration of EGCG itself is not the cause of these aborted 
litters, but rather the stress or volume of the treatment may be causing this artifact. 
 
5.6 EGCG Ameliorates the PA1 Cell Deficit at E9.5 and May be Therapeutic for other 
DS Phenotypes 
In order to understand the effects of EGCG on early mandibular development in 
vivo, Ts65Dn and euploid pregnant females treated with EGCG or PBS were analyzed 
using unbiased stereology under three parameters: NCC number, PA1 volume, and 
embryo volume. Ts65Dn embryos displayed a neural crest cell deficit at E9.5 which 
could be overcome with EGCG treatment on E7 and E8 of development. Interestingly, 
euploid embryos also treated with EGCG showed an increase in NCC number in the PA1. 
Results provided here indicate that similar effects occur in the developing PA1 
regardless of genotype, suggesting EGCG acts similarly in both systems. Due to the 
knowledge presented regarding the ability of EGCG to inhibit Dyrk1a, we hypothesize 
that inhibition of Dyrk1a in the PA1 at E7 and E8 with EGCG treatment is sufficient to 
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cause alterations leading to increased NCCs proliferation to euploid levels observed at 
E9.5. Since Dyrk1a overexpression has been tied with NFAT cytoplasmic localization, a 
decrease in Dyrk1a activity or expression should theoretically lead to more nuclear NFAT 
and thus more transcriptional activity by NFAT. NFAT has many downstream targets, 
some of which include genes tied with homeostasis between proliferation and 
differentiation of cells (HUANG et al. 2011). Therefore, we hypothesize that this inhibition 
of Dyrk1a is sufficient to allow appropriate re-entry of NFAT into the nucleus, permitting 
euploid levels of proliferation of NCC and migration from the NT to PA1.  
Though Dyrk1a has not been specifically studied in other proliferative disorders, 
it may serve as an interesting point of study in the future, in conjunction with 
investigations into NFAT localization. In addition, Dyrk1a inhibitors may also have a far-
reaching effect on DS phenotypes. DYRK1A has also been highly implicated in DS brain 
pathology, including neuronal differentiation and maturation, spatial learning and 
memory deficits, and alterations in brain size and structure (AHN et al. 2006; ALTAFAJ et al. 
2001; CANZONETTA et al. 2008; FOTAKI et al. 2002) and normalization of DYRK1A activity 
has been postulated as a therapy in DS (MAZUR-KOLECKA et al. 2012). Additionally, 
harmine has been tested on neural progenitor cells from Ts65Dn newborn mice in 
culture and has shown a prevention of premature neuronal maturation in trisomic cells 
(MAZUR-KOLECKA et al. 2012). Consequently, inhibition through the use of EGCG should 
lead to similar results and may be a valuable therapeutic in DS in the future.  
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5.7 EGCG Alters Expression of Genes Implicated in Craniofacial Development 
Pathways 
EGCG is known to modify Dyrk1a activity and has been shown to decrease 
Dyrk1a protein levels in the presence of other green tea polyphenols (GUEDJ et al. 2009). 
Little has been established to this point, however, on the mechanism of action for EGCG 
and in particular, how it leads to alterations in the PA1 of the developing E9.5 Ts65Dn 
and euploid embryos. Relative expression analysis using qPCR revealed alterations in 
expression of six genes implicated alone or in part of a developmental pathway in 
craniofacial morphogenesis: Dyrk1, Rcan1, Shh, Gli1, Ptch1, and Ets2. Interestingly, 
relationships between some of these genes have been explored otherwise. For example, 
Dyrk1 can substantially enhance Gli1-dependent transcription (MAO et al. 2002), which 
has a function highly regulated in hedgehog signaling, known for its important role in 
cell proliferation and embryonic patterning (HAMMERSCHMIDT et al. 1997; INGHAM and 
MCMAHON 2001; VON OHLEN and HOOPER 1997). We hypothesize from the results 
presented that EGCG interacts with the feedback loop associated with Dyrk1a 
expression and signaling and also leads to alterations in expression of genes in the 
hedgehog pathway through alterations in Dyrk1a expression and/or Dyrk1a activity 
(Figure 5.3). Furthermore, EGCG may affect other genes through unknown mechanisms 
involved in craniofacial development. For example, Ets2, a gene triplicated in Ts65Dn 
mice encoding a transcription factor, has been shown to affect mesoderm-derived and 
neural crest-derived formative tissues which contribute to cranial skeletal elements 
when its gene dosage is altered in Ts65Dn mice (HILL et al. 2009).  
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5.8 Future Studies 
Aside from its ability to inhibit Dyrk1a and rescue brain weight alteration in 
Dyrk1a transgenic mice (GUEDJ et al. 2009), little is known of the impact EGCG makes on 
the body of mice and embryos treated with the compound, aside from the data 
presented. In order to understand the broad spectrum of impact of EGCG in an in vivo 
system, an intensive evaluation of the mouse being treated, a pregnant female in this 
case, must be performed, including a thorough investigation for anomalies of the major 
organs, bones, and plasma levels of EGCG and in the case of oral gavage usage, and 
appearance of any physical stress of the esophagus. In addition, gross morphological 
evaluation should be performed of embryos throughout development. Current studies 
in our laboratory regarding the use of EGCG to overcome bone deficits in Ts65Dn adult 
mice provide compelling results in favor of EGCG treatment even after the abnormal 
phenotype has already been observed developmentally. Not only does this add to the 
application of use of EGCG treatments, but also reveals the potency of this compound.  
Currently, several clinical trials are in place for DS treatments, including one 
using EGCG to reverse cognitive deficits observed in individuals with DS. The trial is in 
Phase II and will be assessing individuals between the ages of 14 and 29 years for 
alterations in memory and Dyrk1a activity, as well as psychomotor speed, attention, 
coordinator, and quality of life as secondary parameters for assessment. Individuals with 
be orally administered 9 mg/kg body weight of EGCG or a placebo daily for three 
months. The data collection phase of this trial has been completed, but not results are 
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currently available (ClinicalTrials.gov Identifier NCT01394796). Memantine is also 
currently under clinical trial for enhancement of cognitive abilities of young adults with 
DS, assessing neuropsychological parameters dependent on function of the 
hippocampus, as well as performance in a number of neuropsychological benchmarks 
and safety and tolerability assessments. Recruitment of individuals with DS ages 18 to 
32 years to participate in a 5 mg/d week one, 5mg/BID week two, 5 and 10 mg/d divided 
dose week three, and 10 mg/BID week four treatment regimen is currently underway at 
The Children’s Hospital in Colorado, U.S. (ClinicalTrials.gov Identifier NCT01112683). 
Due to the potential translational impact of this research and its current use in 
clinical trials for other purposes, understanding what components of these compounds 
are producing the desired effects will be important in producing more effective and 
specific pharmaceuticals for treatment. While EGCG does appear to have valuable 
pharmaceutical properties, its specificity and impacts on other systems in the body are 
unknown and altering the structure or properties of this compound may allow for 
increased specificity with reproducible and predictable impacts throughout the body. 
This research will be crucial in steps toward advancing EGCG as a therapeutic by 
optimizing bioavailability, activity, and toxicity of various compounds. An understand 
the potential broad spectrum genetic effects of these compounds will also be vital, 
perhaps through the use of microarray of cells or various tissues exposed to EGCG 
treatment. Concomitantly, understanding the specific interactions of EGCG with other 
genes or protein produces aside from Dyrk1a should be investigated to appropriately 
define mechanisms of action for this compound.
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Table 1.1 Higher prevalence of DS births to advanced age women. Advanced maternal 
age is a risk factor for DS. Despite more children with DS being born to younger mothers, 
prevalence of DS births is higher in older women due to lower overall birth rates in older 
women. Data were collected from white individuals with DS, total live births, reported 
risk rates per 1000 live births, and rates corrected for birth certification under-reporting 
in Ohio 1970-1983. Corrected rates were obtained by dividing the reported rates by the 
percentage of reporting: 0.367. Modified from Huether et al., 1998 (HUETHER et al. 1998). 
 
Maternal Age Down syndrome Live births Rate/1000 births Corrected rate  
≤ 15 4.69 14,361 0.33 0.89 
16 4.00 31,556 0.13 0.35 
17 11.39 58,718 0.19 0.53 
18 11.69 86,648 0.14 0.37 
19 27.08 113,332 0.24 0.65 
20 28.40 126,094 0.23 0.61 
21 41.60 137,010 0.30 0.83 
22 35.60 147,035 0.24 0.66 
23 33.00 154,182 0.21 0.58 
24 47.22 153,738 0.31 0.84 
25 45.55 148,831 0.31 0.83 
26 46.79 140,365 0.33 0.91 
27 47.55 128,241 0.37 1.01 
28 32.76 113,829 0.29 0.79 
29 39.27 97,647 0.40 1.10 
30 37.56 80,573 0.47 1.27 
31 31.78 64,795 0.49 1.34 
32 30.33 50,963 0.60 1.62 
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Table 1.1 Continued 
33 25.71 40,161 0.64 1.74 
34 24.29 31,496 0.77 2.10 
35 27.21 24,136 1.13 3.07 
36 23.12 18,611 1.24 3.38 
37 24.66 13,936 1.77 4.82 
38 36.33 10,737 3.38 9.22 
39 24.36 8167 2.98 8.13 
40 33.34 5963 5.59 15.23 
41 14.09 4185 3.37 9.17 
42 15.62 2834 5.51 15.02 
43 12.12 1708 7.09 19.33 
44 14.93 962 15.52 42.29 
45 6.95 467 14.88 40.56 
46 5.95 220 27.05 73.71 
47 1.22 90 13.60 37.06 
48 0.00 21 0.00 0.00 
≥49 1.00 22 45.46 123.86 
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Figure 1.1: Mosaicism may result from a genetically normal or trisomic zygote due to 
mitotic errors. Mosaicism can occur through numerous mechanisms including 
nondisjunction from the normal zygote during the second division or in the trisomic 
zygote in either the first or second divisions. Modified from Richards, 1969 (RICHARDS 
1969).  
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Figure 1.2: Susceptibility regions for various phenotypes have been developed from 
phenotypic mapping. Using 30 cases of partial trisomy to map phenotypes of these 
individuals, Lyle and colleagues developed regions of Hsa 21 which likely play a role in 
the development of a single phenotype. As outlined above, phenotypes including 
craniofacial phenotypes, cardiac anomalies, hypotonia, and ID have all been mapped to 
various regions of Hsa 21 and termed ‘susceptibility regions.’ Each phenotype described 
is represented by a score (y-axis) designating the likelihood of a feature mapping to a 
position on Hsa 21 (x-axis). Modified from Lyle et al., 2009 
(LYLE et al. 2009). 
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Figure 1.3: Mice display a high level of homology with humans in craniofacial bones.  
Placement of craniofacial bones and the proximity of these bones with respect to one 
another in mice are highly reflective of that in humans. The location of these bones is 
crucial to maintain homology in signaling pathways to which the developing form of 
these structures are exposed. The similarities in the craniofacial skeletons between 
humans and mice allow for comparisons to be made between the developmental 
precursor to the mandible in the Ts65Dn mouse model of DS and that of individuals with 
DS in order to better understand the genotype-phenotype relationships occurring in the 
facial skeleton. Modified from Richtsmeier et al., 2000 (RICHTSMEIER et al. 2000). 
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Figure 1.4: Hsa 21 genes can be found on Mmu 10, 16, and 17 with differing 
contributions of genes from each Mmu chromosome. The genes found on Hsa 21 can 
be found on Mmu 16, Mmu 10, and Mmu 17. Mmu 10 and 17 contain a multitude of 
genes other than those found on Hsa 21, compounding the difficulty of chromosomal 
engineering for only Hsa 21 genes in mouse models. Modified from Antonarakis et al., 
2004 (ANTONARAKIS et al. 2004). 
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Figure 1.5: Mouse models of Down syndrome.Mouse models trisomic for orthologs 
from Hsa 21 have been developed to better understand how specific genes contribute 
to a number of DS phenotypes. The Ts65Dn mouse is the most commonly used model 
and contains a triplication for about half of the Hsa 21 orthologs; Ts1Rhr mice are 
trisomic for approximately 33 of the genes triplicated in Ts65Dn mice; and Tc1 mice are 
transchromosomic, containing the most Hsa 21 orthologs in three copies of all DS mouse 
models currently developed. Several other mouse models have been developed to 
better understand the contribution of specific chromosomes and regions associated 
with DS, including Ts1Cje, Ts1Yey, Ts1Yah and other small segmentally trisomic mice. 
Modified from Das and Reeves, 2011 (DAS and REEVES 2011). 
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Figure 1.6: DYRK1A and RCAN1 are involved in multiple biological processes and 
pathways.(A) DYRK1A is involved in multiple cellular pathways including biochemical 
processes and genetic regulation of several genes implicated in DS, including APP, the 
transcription factor NFAT and itself. (B) RCAN1 is also involved in numerous biological 
processes including angiogenesis, tumorigenesis, learning and memory and regulation 
of neurotransmitter release. RCAN1 indirectly effects NFAT localization through 
calcineurin, leading to a link between DYRK1A and RCAN1 in their regulation of NFAT. 
Modified from Park et al., 2009 (PARK et al. 2009). 
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Figure 1.7: Regulation of NFAT localization by DYRK1A and RCAN1.(A) DYRK1A and 
DSCR1 (RCAN1) when expressed at euploid levels, regulate the localization of NFAT 
through phosphorylation or inhibition of the phosphatase calcineurin, respectively. (B) 
When DYRK1A and RCAN1 are in three copies, such as in the case of trisomy 21, it is 
hypothesized that increased phosphorylation of NFAT leads to increased cytoplasmic 
localization, coupled with increase inhibition of calcineurin, leading to a synergistic 
cytoplasmic localization of NFAT. The overexpression of DYRK1A and DSCR1 (RCAN1) 
would thus lead to decreased expression of genes which rely on transcriptional 
activation from NFAT. Modified from Epstein 2006 (EPSTEIN 2006). 
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Figure 1.8: Natural and synthetic DYRK1A inhibitors.(A) Epigallocatechin-3-gallate 
(EGCG) and (B) harmine exist naturally as plant-derived substances known to strongly 
inhibit DYRK1A. (C) INDY has undergone very little study, but has profound impacts on 
DYRK1A expression and an ability to rescue NFAT signaling. Screening for novel DYRK1A 
inhibitors revealed six novel compounds of which compounds 3 (D) and 5 (E) were 
selected for further study. Modified from Wang et al., 2011. (WANG et al. 2011)  
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Figure 2.1: The use of fluorescence in situ hybridization (FISH) to genotype Ts65Dn 
mice and embryos. Prior to the development of primers to amplify the breakpoint 
between the Mmu 16 and Mmu 17 centromere segment in Ts65Dn, FISH was utilized. (A) 
Euploid fibroblasts provide two fluorescent signals, while (B) trisomic fibroblasts show 
three fluorescent signals per cell. Modified from Strovel et al., 1999 (STROVEL et al. 1999). 
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Figure 2.2: Utilization of the scratch test for quantification of migration. Cells grown to 
confluency on fibronectin-coated coverslips were subjected to the scratch test assay as 
described by Liang and colleagues (LIANG et al. 2007). For each sample, a diagonal 
scratch was made across the cell surface using a pipet tip as illustrated. Media was 
changed after the scratch was made to remove any debris and cells remaining in the 
scratch were quantified to be eliminated from subsequent counts.  
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Figure 2.3: A plate schematic for qPCR analysis of RNA. For qPCR analysis of RNA 
derived from the PA1 and NT, plates were set up as shown above. Rows A and E were 
used for the reference gene probe, rows B and F for target gene 1, rows C and G for 
target gene 2, and rows D and H for target gene 3. Samples were divided as shown with 
trisomic samples (s1, s3, s5, s7, s9, and s11) on the top half of the plate and euploid 
samples (s2, s4, s6, s8, s10, and s12) on the bottom half of the plate. For each well, 15 µl 
of probe master mix corresponding to the appropriate gene were used, then 5 µl of the 
corresponding sample cDNA.  
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Figure 3.1: Dysregulation of Hsa 21 genes found in three copies in Ts65Dn mice occurs 
in the PA1 and NT early in development. (A) For RNA extraction from E9.25 (15-18 
somites) and E9.5 (21-24 somites), the PA1 and NT were dissected as shown and 
analyzed for each embryo. (B) Similar trends of Rcan1 and Dyrk1a regulation in the 
E9.25 PA1 and NT, including increased expression of Rcan1 (p ≤ 0.05, PA1 and NT) and a 
slight decrease in expression of Dyrk1a (p ≤ 0.05, PA1 and NT) (N = 5 Eu, 5 Ts PA1; 5 Eu, 
5 Ts NT). (C) A complete reversal in relative expression to increased expression of 
Dyrk1a (p ≤ 0.05, PA1 and NT) and decreased expression of Rcan1 (p ≤ 0.05, PA1 and NT) 
compared to euploid levels characterizes E9.5 PA1 and NT genetic regulation when 
compared to values at E9.25. Dyrk1a is highly expressed in both structures (p ≤ 0.05, 
PA1 and NT), while Rcan1 is downregulated (p ≤ 0.05, PA1 and NT) (N = 7 Eu, 7 Ts PA1; 5 
Eu, 5 Ts NT). (D) Keeping with this trend, RNA in the E13.5 PA1 reveals an upregulation 
of Rcan1 (p ≤ 0.01) and downregulation of Dyrk1a (p ≤ 0.05) (N= 9 Eu, 9 Ts). Expected 
euploid levels of expression are equal to 1 for relative expression comparisons. For 
statistical analysis, 2-tailed Students t-tests were used and are shown in the graph as * 
for p ≤ 0.05. 
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Figure 3.2: Trisomic genes Dyrk1a and Rcan1 display alterations in expression 
dependent on time in the PA1. Changes in over- and underexpression of expression of 
Dyrk1a and Rcan1 appear to occur over time, especially around midgestation of the 
developing Ts65Dn mouse embryo. At E9.25, Dyrk1a is downregulated (p ≤ 0.05), while 
Rcan1 is upregulated (p ≤ 0.05) (N = 5 Eu, 5 Ts). At E9.5, Dyrk1a is then upregulated (p ≤ 
0.05) and Rcan1 is downregulated (p ≤ 0.05) from euploid levels (N = 7 Eu, 7 Ts). At E10, 
this relationship again switches and Dryk1a is downregulated (p ≤ 0.05), while Rcan1 is 
upregulated (p ≤ 0.05) (N = 5 Eu, 5 Ts). Later in development at E13.5, Dyrk1a and Rcan1 
are both upregulated (p ≤ 0.01 for both genes) (N = 9 Eu, 9 Ts), continuing to show that 
alterations in the expression of these two changes occur frequently throughout 
midgestation. Expected euploid levels of expression are equal to 1 for relative 
expression comparisons. For statistical analysis, 2-tailed Students t-tests were used and 
are shown in the graph as * for p ≤ 0.05. Error bars indicate standard error of the mean. 
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Figure 3.3: Expression Dysregulation of Dyrk1a and Rcan1 in the E9.5 Ts1Rhr PA1. 
Expression of Rcan1, Dyrk1a, and Ets2, three genes hypothesized or known to be 
involved in craniofacial development were assessed for relative expression in the Ts1Rhr 
E9.5 PA1. Ts1Rhr mice were bred on two genetically different backgrounds to account 
for differences between methodologies in several studies. Despite genetic differences in 
background, Ts1Rhr E9.5 PA1 display genetic dysregulation, including upregulation of 
Dyrk1a. Changes in Rcan1 and Ets2 also appear to be present, but differ by strain. 
Expected euploid levels of expression are equal to 1 for relative expression comparisons. 
For statistical analysis, 2-tailed Students t-tests were used and are shown in the graph as 
* for p ≤ 0.05. Error bars indicate standard error of the mean. 
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Figure 3.4: Ts65Dn PA1 are deficient in cellular proliferation. Modifications to improve 
methodology and precise data collection from that described in Roper et al., 2009 were 
made in this proliferation assay. Ts65Dn mice display reduced proliferation in the PA1 (p 
≤ 0.05) with respect to their euploid littermates (N = 7 Eu, 6 Ts). No alteration in 
proliferation of cells from the E9.5 NT was present (p = 0.92) (N = 7 Eu, 6 Ts). For 
statistical analysis, 1-tailed Students t-tests were used and are shown in the graph as * 
for p ≤ 0.05. Error bars indicate standard error of the mean. 
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Figure 3.5: Ts65Dn proliferation and migration deficits observed in culture. When cells 
were observed on the same day after plating, dramatic differences in plate coverage 
were observed between trisomic and euploid samples. After growing each sample to 
confluency, the sample was subjected to the scratch assay. Dramatic differences can be 
observed in the decreased migration of Ts65Dn PA1 cells back into the scratch when 
compared with the euploid cells above. Treatment with 25µM EGCG appears to visibly 
rescue these deficiencies from confluency through the termination of the assay. 
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Figure 3.6: Ts1Rhr display no significant migration deficits in the PA1 or NT. PA1 (N = 
11 Eu, 11 Ts) and NT cells (N = 11 Eu, 11 Ts) derived Ts1Rhr embryos migrate at euploid 
levels from 24 hours after the initiation of the scratch assay through the termination of 
the assay at 72 hours. No significant differences were found throughout the assay. For 
statistical analysis, 2-tailed Students t-tests were used (p = 0.10 PA1 24 hours; p = 0.74 
PA1 48 hours; p = 0.93 PA1 72 hours; p = 0.57 NT 24 hours; p = 0.63 NT 48 hours; p = 
0.12 NT 72 hours). Error bars indicate standard error of the mean. 
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Figure 3.7: Ts65Dn PA1 cells display a proliferation deficit which can be overcome with 
EGCG treatment. Cells from the PA1 of E9.5 Ts65Dn embryos display impaired 
proliferation compared to euploid cells (p ≤ 0.01) (N = 8 Eu, 7 Ts). These cells respond in 
a dose-dependent manner to treatment, with a significant increase in proliferation with 
the addition of 10µM EGCG (p ≤ 0.05) and optimal proliferation occurring with 25µM 
EGCG treatment for 4 hours (p ≤ 0.001) (N = 10 Ts, 10 Eu). Addition of 100µM EGCG led 
to an excessive increase in proliferation above euploid levels (p ≤ 0.001). Interestingly, 
cell from the NT display no deficit in proliferation, but are still affected by EGCG 
treatment. A dose of 10µM (N = 10 Eu, 10 Ts) appears to adversely affect proliferation of 
cells from NT (p ≤ 0.01), while 25µM EGCG produces no change from untreated trisomic 
cells (p = 0.89). A significant increase in proliferation can be seen, however, in treatment 
with 100µM EGCG (N = 10 Eu, 10 Ts) to above euploid levels (p ≤ 0.001). For statistical 
analysis, a 2-tailed Students t-test was used and are shown in the graph as * for p ≤ 0.05. 
Error bars indicate standard error of the mean. 
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Figure 3.8: Ts65Dn PA1 and NT cells display migration deficits at E9.5 which can be 
overcome with EGCG treatment. Cells from the PA1 of Ts65Dn E9.5 embryos display an 
initial migration deficit (p ≤ 0.001) which is not overcome through the progression of the 
scratch assay (N = 11 Eu, 8 Ts). However, treatment with both 10µM (p ≤ 0.001) (N = 8 
Eu, 8 Ts) and 25µM EGCG (p ≤ 0.001) (N = 7 Eu, 7 Ts) is sufficient to rescue this deficit 
within 24 hours. Migration continues to be rescued in the PA1 at 48 and 72 hours (p ≤ 
0.01 for all conditions). Migration in the NT is deficient at 24 hours post assay initiation, 
but appears to reach euploid levels of migration by the completion of the assay. 
Treatment with 10µM (p ≤ 0.05) and 25µM (p ≤ 0.05) rescues this initial migration deficit 
and maintains cell migration using 25µM (p ≤ 0.05) at euploid levels through the 
termination of the assay. For statistical analysis, 2-tailed Students t-tests were used and 
are shown in the graph as * for p ≤ 0.05. Error bars indicate standard error of the mean. 
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Figure 3.9: Ts1Rhr display no proliferation deficit in the PA1, but a slight deficit in NT 
at E9.5. Cells from the PA1 of E9.5 Ts1Rhr embryos display a slightly elevated level of 
proliferation (N = 8 Eu, 7 Ts PA1), mimicking their known phenotype of a larger PA1 than 
euploid littermates at this time point and as adults (DEITZ and ROPER 2011). Treatment 
with EGCG had no effect on the proliferation of PA1 cells at 10 µM (N = 8 Eu, 7 Ts), 25 
µM (N = 8 Eu, 8 Ts), and 100 µM (N = 6 Eu, 6 Ts). Cells from the NT of these embryos 
displayed a slight decrease in proliferation (N = 8 Eu, 7 Ts) which was ameliorated with 
EGCG treatment at 10 µM (N = 8 Eu, 7 Ts), 25 µM (N = 8 Eu, 8 Ts), and 100µM (N = 6 Eu, 
6 Ts). For statistical analysis, 2-tailed Students t-tests were used and are shown in the 
graph as * for p ≤ 0.05. Error bars indicate standard error of the mean. 
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Figure 3.10: Ts1Rhr PA1 and NT migration is not significantly altered by EGCG. 
Assessment for migration of E9.5 Ts1Rhr PA1 and NT revealed no significant deficit in 
migration of cells from either structure (p = 0.11 PA1; p = 0.12 NT) (N = 10 Eu, 10 Ts PA1; 
10 Eu, 10 Ts NT). While migration was slightly increased in PA1 cells treated with 10µM 
EGCG (p ≤ 0.05), but not NT cells (p = 0.31) initially, treatment of NT cells with 10µM led 
to some decrease in proliferation at 48 (p ≤ 0.05) and 72 hours (p ≤ 0.05 ) (N = 10 Eu, 8 
Ts PA1; 10 Eu, 8 Ts NT), treatment of PA1 and NT cells with 100µM EGCG had no effects 
(p = 0.79 PA1, p = 0.55) (N = 7 Eu, 7 Ts PA1; 10 Eu, 10 Ts NT) on migration. For statistical 
analysis, 2-tailed Students t-tests were used and are shown in the graph as * for p ≤ 0.05. 
Error bars indicate standard error of the mean. 
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Figure 3.11: Harmine corrects the E9.5 Ts65Dn PA1 proliferation deficit and increases 
euploid proliferation. Treatment of PA1 cells with 1µM (N = 8 Eu, 8 Ts) and 10µM 
harmine (N = 8 Eu, 8 Ts) was sufficient to rescue proliferation to a euploid level (p ≤ 0.01; 
p ≤ 0.01, respectively). Assessment of euploid cells alone with the same treatment 
revealed dramatic increases in proliferation of PA1 cells (p ≤ 0.001 for 1µM and 10µM 
treatments). A slight proliferation deficit seen in NT untreated cells (p = 0.22) can be 
altered to increase proliferation of trisomic and euploid cells, with significant increases 
in euploid cell proliferation at 1µM (p ≤ 0.05) and 10µM (p ≤ 0.05) (N = 8 Eu, 8 Ts at 1µM; 
N = 8 Eu, 8 Ts at 10µM). For statistical analysis, 2-tailed Students t-tests were used and 
are shown in the graph as * for p ≤ 0.05. Error bars indicate standard error of the mean. 
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Figure 3.12: Harmine increases Ts1Rhr PA1 and NT proliferation in a dose-dependent 
manner. Slight decreases in NT proliferation (p ≤ 0.05) (N = 7 Eu, 7 Ts) were overcome 
by 1µM harmine (N = 7 Eu, 7 Ts) to euploid levels in the NT (p ≤ 0.05). Harmine 
treatment also increased the proliferation of euploid cells from the PA1 (p ≤ 0.05) and 
the NT (p ≤ 0.001). For statistical analysis, 2-tailed Students t-tests were used and are 
shown in the graph as * for p ≤ 0.05. Error bars indicate standard error of the mean. 
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Figure 4.1: EGCG treatment does not adversely impact litter sizes. Embryos from 
pregnant euploid (N = 38 pups, 6; N = 18 pups, 2 litters for PBS) and Ts65Dn (N = 25 pups, 
4 litters EGCG; N = 10 pups, 2 litters for PBS treatment) females treated by oral gavage 
twice daily on E7 and E8 with EGCG or PBS, and sacrificed on E9.5 were not adversely 
affected by EGCG treatment, as shown by no reduction in litter size. The number of 
embryos present in Ts65Dn mothers receiving EGCG did not differ significantly from 
euploid mothers receiving EGCG, though it appears that litter sizes increased with EGCG 
treatment. For statistical analysis, 1-tailed Students t-tests were used. Error bars 
indicate standard error of the mean. 
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Figure 4.2: EGCG treatment does not adversely impact developmental staging among 
treatment groups or between genotypes. Pups from treated and untreated mothers 
were analyzed by genotype for somite stage to understand the impacts of EGCG on 
development. No differences were seen between EGCG or PBS treatment groups or 
trisomic or euploid genotype, indicating no overall developmental effects by EGCG in 
vivo (N = 43 pups Eu + EGCG; N = 9 pups Ts + EGCG; N = 14 pups Eu + PBS; N = 4 pups Ts 
+ PBS). For statistical analysis, 1-tailed Students t-tests were used. Error bars indicate 
standard error of the mean. 
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Figure 4.3: Developmental stage distribution is not altered by EGCG. Though increased 
variability appears to be present in litters receiving EGCG in vivo, median and average 
somite stages of E9.5 embryos receiving EGCG or PBS do not differ significantly between 
groups. Distributions are designated into four groups: by genotype of the mother 
combined with treatment. Each distribution group cluster indicates a single litter and 
the somite stages of the individual embryos in that litter (N = 8 litters, 47 pups for Eu 
mom + EGCG; N = 4 litters, 25 pups for Ts mom + EGCG; N = 2 litters, 10 pups for Ts 
mom + PBS; N = 1 litter, 8 pups for Eu mom + PBS).  
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Figure 4.4: EGCG treatment leads to an increase in cell number in the trisomic and 
euploid PA1. Stereological analysis of E9.5 EGCG and PBS treated embryos revealed a 
NCC deficit in trisomic embryos treated with PBS (N = 4) compared to euploid embryos 
treated with PBS (N = 4) (p ≤ 0.01). When trisomic embryos were treated with EGCG (N = 
4), however, this deficit was ameliorated to euploid levels (p = 0.082). However, 
treatment of euploid embryos with EGCG (N = 4), led to an increase in NCC above 
euploid embryos treated with PBS (p ≤ 0.05). For statistical analysis, 2-tailed Students t-
tests were used and are shown in the graph as * for p ≤ 0.05. Error bars indicate 
standard error of the mean. 
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Figure 4.5: EGCG treatment increases PA1 volume in trisomic and euploid embryos. 
Trisomic PBS treated embryos (N = 4) display a smaller PA1 volume than euploid PBS 
treated embryos (N = 4) (p ≤ 0.001). Treatment of Ts65Dn embryos with EGCG (N = 4) 
improves PA1 volume to above trisomic PBS PA1 volume (p ≤ 0.001), but not to PBS 
treated euploid PA1 volume (p ≤ 0.01). Treatment of euploid embryos with EGCG (N = 4) 
leads to increased PA1 above PBS treated euploid PA1 volume (p ≤ 0.05). For statistical 
analysis, 2-tailed Students t-tests were used and are shown in the graph as * for p ≤ 0.05. 
Error bars indicate standard error of the mean. 
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Figure 4.6: EGCG treatment increases embryo volume in euploid, but not trisomic 
embryos. Ts65Dn PBS treated embryos (N = 4) are smaller than euploid PBS treated 
embryos (N = 4) as measured through stereological analysis of embryonic volume (p ≤ 
0.001). Treatment of trisomic embryos with EGCG (N = 4) does not lead to a significant 
increase in volume compared to PBS treated euploid embryos, but does increase 
embryonic volume in comparison to PBS treated trisomic embryos. Euploid embryos 
treated with EGCG (N = 4) have a larger embryo volume than euploid treated PBS 
embryos, but this value is not significant (p = 0.092). For statistical analysis, 2-tailed 
Students t-tests were used. Error bars indicate standard error of the mean. 
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Figure 4.7: EGCG exposure leads to expression alterations of genes involved in 
pathways impacting craniofacial development. Baseline expression of Dyrk1a, Rcan1, 
Shh, Gli1, Ptch1, and Ets2 reveals alterations in expression from euploid values (a value 
of 1). Expression of these genes is altered in several cases in trisomic PA1 receiving 
EGCG treatment with most achieving near euploid values of relative expression (N = 3 Ts 
receiving EGCG, 3Eu receiving EGCG, 3 Ts receiving PBS, and 3 Eu receiving PBS). 
Expected euploid levels of expression are equal to 1 for relative expression comparisons. 
For statistical analysis, 2-tailed Students t-tests were used and are shown in the graph as 
* for p ≤ 0.05. Error bars indicate standard error of the mean.  
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Figure 5.1: Loss of expression of Dyrk1a leads to upregulation of Rcan1. Dyrk1a and 
Rcan1 are hypothesized to regulate the expression of one another. Using RNA extracted 
from the PA1 of a Dyrk1a heterozygous mouse, qPCR revealed a subsequent 
upregulation of Rcan1 (p ≤ 0.05) and downregulation of Dyrk1a (p ≤ 0.05) due to 
deletion of one copy of the gene (N = 4 Eu, 4 Ts PA1; 4 Eu, 4 Ts NT). These two genes 
appear to regulate one another in the PA1 at midgestation. Expected euploid levels of 
expression are equal to 1 for relative expression comparisons. For statistical analysis, 2-
tailed Students t-tests were used and are shown in the graph as * for p ≤ 0.05. Error bars 
indicate standard error of the mean. 
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Figure 5.2: Litter survival in pregnant Ts65Dn and euploid mothers receiving EGCG is 
not altered by dosage. Litter sizes from pregnant females receiving EGCG or PBS on E7 
and E8 were quantified at E9.5 when embryos were dissected. A lost litter (resorbed) 
was classified as the presence of uterine swelling with the appearance or presence of 
embryonic tissue either at the time of dissection or within the two days prior to the 
dissection. Proportionally, fewer litters were lost from euploid mothers receiving 
treatment than trisomic mothers receiving treatment overall. 
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Figure 5.3: EGCG-related expression alterations of genes involved in pathways 
impacting craniofacial development may occur through changes in Dyrk1a activity. 
Expression of Dyrk1a is altered in the trisomic E9.5 PA1 and that activity of this gene is 
known to be altered by treatment with EGCG. As depicted, Dyrk1 interacts with Gli1, a 
transcription factor, which transcribes genes impacting proliferation. Hypothesized 
normalization of Dyrk1a activity may lead to normalization of this transcriptional 
pathway when EGCG is present, leading to normalization of proliferation in the E9.5 
trisomic PA1. Image provided by Biocarta 
(http://cgap.nci.nih.gov/Pathways/BioCarta/m_shhPathway). 
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